API
Navigational tip: click on "leads to" or the ID column to navigate to the KE Relationship.

KE Relationships

Id Upstream Event Relationship Type Downstream Event
5 Reduction, 17beta-estradiol synthesis by ovarian granulosa cells leads to Reduction, Plasma 17beta-estradiol concentrations
9 Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity leads to Decreased, Mitochondrial fatty acid beta-oxidation
750 Activation, 5HT2c leads to N/A, Unknown
1857 ACh Synaptic Accumulation leads to Activation, Muscarinic Acetylcholine Receptors
454 ACh Synaptic Accumulation leads to Increased, Atrioventricular block and bradycardia
456 ACh Synaptic Accumulation leads to Increased Cholinergic Signaling
459 ACh Synaptic Accumulation leads to AchE Inhibition
11 AchE Inhibition leads to ACh Synaptic Accumulation
2653 AchE Inhibition leads to Activation of Cyp2E1
449 AchE Inhibition leads to Increased, Atrioventricular block and bradycardia
450 AchE Inhibition leads to Respiratory distress/arrest
451 AchE Inhibition leads to Increased Cholinergic Signaling
452 AchE Inhibition leads to Increased Mortality
453 AchE Inhibition leads to Decreased, Population trajectory
2007 AchE Inhibition leads to Cardiovascular dysregulation
2014 AchE Inhibition leads to Impaired coordination and movement
2016 AchE Inhibition leads to Decrease, Population growth rate
16 Altered expression of AHR/ARNT pathway-dependent genes leads to Altered, Cardiovascular development/function
17 Altered expression of AHR/ARNT pathway-dependent genes leads to Up Regulation, CYP1A1
2568 Activation, AhR leads to Increase, Inflammation
2569 Activation, AhR leads to Apoptosis
2570 Activation, AhR leads to Increased, Motility
2571 Activation, AhR leads to Increased, Migration (Endothelial Cells)
2572 Activation, AhR leads to Increased, Invasion
18 Activation, AhR leads to Altered expression of AHR/ARNT pathway-dependent genes
19 Activation, AhR leads to Up Regulation, CYP1A1
2883 Activation, AhR leads to Induction, Upregulation of glucuronyltransferase activity
2888 Activation, AhR leads to N/A, Liver Steatosis
869 Activation, AhR leads to Induction, CYP1A2/CYP1A5
1656 Activation, AhR leads to Up Regulation, SCD-1
2687 Activation, AhR leads to Increase, slincR expression
2688 Activation, AhR leads to Decrease, sox9 expression
2689 Activation, AhR leads to Smaller and morphologically distorted facial cartilage structures
1992 Activation, AhR leads to Increase, DNMT expression
972 Activation, AhR leads to dimerization, AHR/ARNT
2765 Activation, AhR leads to Altered, Cardiovascular development/function
984 Activation, AhR leads to Increase, Early Life Stage Mortality
473 Activation, AhR leads to Inhibition, Mitochondrial fatty acid beta-oxidation
495 Activation, AhR leads to Up Regulation, CD36
496 Activation, AhR leads to Increased, FA Influx
499 Activation, AhR leads to Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)
506 Activation, AhR leads to Up Regulation, LDLR (low density lipoprotein receptor)
509 Activation, AhR leads to Suppression, VLDL secretion
31 Agonism, Androgen receptor leads to Reduction, Gonadotropins, circulating concentrations
32 Agonism, Androgen receptor leads to Reduction, Testosterone synthesis by ovarian theca cells
2349 Agonism, Androgen receptor leads to Increased, Male Biased Sex Ratio
2918 Agonism, Androgen receptor leads to Increased, gene expression of AR
1384 Agonism, Androgen receptor leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
1385 Agonism, Androgen receptor leads to Reduction, Vitellogenin synthesis in liver
2926 Agonism, Androgen receptor leads to Reduction, the ratio of E2/11-KT in plasma
2260 Agonism, Androgen receptor leads to Increased, Differentiation to Testis
2123 Antagonism, Androgen receptor leads to AGD, decreased
2130 Antagonism, Androgen receptor leads to Decrease, AR activation
2133 Antagonism, Androgen receptor leads to nipple retention, increased
2201 Antagonism, Androgen receptor leads to Altered, Transcription of genes by AR
33 N/A, Androgen receptor, Antagonism leads to Altered, Transcription of genes by AR
35 N/A, Androgen receptor, Antagonism leads to Alteration, Wnt pathway
36 Reduction, Angiogenesis leads to Impairment, Endothelial network
43 Decrease, Aromatase (Cyp19a1) leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
45 Inhibition, Aromatase leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
2350 Inhibition, Aromatase leads to Increased, Male Biased Sex Ratio
2144 Inhibition, Aromatase leads to Reduction, E2 Synthesis by the undifferentiated gonad
2167 Inhibition, Aromatase leads to Increased, Differentiation to Testis
1767 Inhibition, Aromatase leads to Altered regulation, Alpha hemoglobin
51 Increased Cholinergic Signaling leads to Decrease, Population growth rate
2410 Increased Cholinergic Signaling leads to Neuronal network function, Decreased
2412 Increased Cholinergic Signaling leads to Cognitive Function, Decreased
434 Increased Cholinergic Signaling leads to Increased Mortality
457 Increased Cholinergic Signaling leads to Respiratory distress/arrest
2005 Increased Cholinergic Signaling leads to Cardiovascular dysregulation
2011 Increased Cholinergic Signaling leads to Impaired coordination and movement
2823 Decrease, Mitochondrial ATP production leads to Decrease, Cardiac contractility
1601 Decrease, Mitochondrial ATP production leads to Decrease, Oogenesis
1873 Decrease, Mitochondrial ATP production leads to Increase, Necrosis
1670 Decrease, Mitochondrial ATP production leads to Decrease, Leaf cell mitosis
1682 Decrease, Mitochondrial ATP production leads to Increase, Cytotoxicity (renal tubular cell)
1739 Decrease, Mitochondrial ATP production leads to Decrease, Growth
1750 Decrease, Mitochondrial ATP production leads to Increase, Apoptosis
2551 Decrease, Mitochondrial ATP production leads to Decrease, Reproduction
927 Inhibition, Bile Salt Export Pump (ABCB11) leads to Bile accumulation, Pathological condition
59 Reduction, Ca and HCO3 transport to shell gland leads to Reduction, Eggshell thickness
60 Increase, Ca++ (intracellular) leads to Disruption, Mitochondrial electron transport chain
61 Inhibition, Ca++ ATPase leads to Increase, Ca++ (intracellular)
62 Decreased, Calcium influx leads to Impairment, Learning and memory
347 Decreased, Calcium influx leads to BDNF, Reduced
66 Up Regulation, CD36 leads to Increase, FA Influx
2262 Up Regulation, CD36 leads to Increased, Fatty acid uptake
501 Up Regulation, CD36 leads to Increased, FA Influx
1830 Cell injury/death leads to Necrotic Tissue
1831 Cell injury/death leads to Activation, Tissue resident cells (Kuppfer cells)
2875 Cell injury/death leads to Hippocampal Physiology, Altered
67 Cell injury/death leads to Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
68 Cell injury/death leads to Activation, Stellate cells
1863 Cell injury/death leads to Neurodegeneration
2890 Cell injury/death leads to Leukocyte recruitment/activation
355 Cell injury/death leads to Synaptogenesis, Decreased
364 Cell injury/death leads to N/A, Neurodegeneration
365 Cell injury/death leads to Neuroinflammation
1688 Cell injury/death leads to Neuronal network function, Decreased
924 Cell injury/death leads to Release, Cytokine
1718 Cell injury/death leads to Tissue resident cell activation
2767 Cell injury/death leads to Decrease, Growth
1776 Cell injury/death leads to Increased pro-inflammatory mediators
69 Proliferation, Cell proliferation in the absence of cytotoxicity leads to Hyperplasia, Hyperplasia
70 Induction, Chitin degradation and resorption leads to Induction, Pre-mature molting
667 Reduction, Ionotropic GABA receptor chloride channel conductance leads to Reduction, Neuronal synaptic inhibition
77 Activation, ChREBP leads to Synthesis, De Novo FA
483 Activation, ChREBP leads to Increased, De Novo FA synthesis
82 Accumulation, Collagen leads to N/A, Liver fibrosis
2139 Accumulation, Collagen leads to Lung fibrosis
1629 Accumulation, Collagen leads to Pulmonary fibrosis
88 N/A, Covalent binding to protein, possibly lysine residue leads to Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways
1700 N/A, Covalent binding to protein, possibly lysine residue leads to Activation, Dendritic Cells
93 Production, Critical Metabolites (CGA 330050 and CGA 265307) leads to Induction, Liver “Dysfunctional” Changes by CGA 330050
94 Reduction, Cumulative fecundity and spawning leads to Decrease, Population growth rate
2142 Reduction, Cumulative fecundity and spawning leads to Decline, Population
2924 Reduction, Cumulative fecundity and spawning leads to Decreased, Population trajectory
95 Inhibition, Cyclooxygenase activity leads to Reduction, Prostaglandin E2 concentration
670 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandin F2alpha synthesis, ovary
681 Inhibition, Cyclooxygenase activity leads to Decreased, Prostaglandin F2alpha synthesis, ovary
686 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandins, ovary
689 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandin E2 concentration, hypothalamus
2887 Up Regulation, CYP1A1 leads to Increase, ROS
96 Up Regulation, CYP1A1 leads to Peptide Oxidation
104 Up Regulation, CYP1B1 leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
108 Release, Cytokine leads to Increase, Inflammation
2454 Release, Cytokine leads to Platelet activation, Increased
2455 Release, Cytokine leads to Neutrophil activation, Increased
925 Release, Cytokine leads to Infiltration, Inflammatory cytokines
1963 Release, Cytokine leads to Recruitment of inflammatory cells
994 Release, Cytokine leads to Infiltration, Inflammatory cells
110 Synthesis, De Novo FA leads to Accumulation, Triglyceride
23 Alkylation, DNA leads to Increase, Heritable mutations in offspring
24 Alkylation, DNA leads to Inadequate DNA repair
25 Alkylation, DNA leads to Increase, Mutations
901 Alkylation, DNA leads to Increase, Cancer
1343 Increase, EcR agonism leads to Increase, E75b expression
116 Increase, EcR agonism leads to Induction, Chitin degradation and resorption
998 Increase, EcR agonism leads to Decrease, Circulating ETH
999 Increase, EcR agonism leads to Decreased, synthesis and secretion of molting fluid proteases
1007 Increase, EcR agonism leads to Decreased, Synthesis of molting fluid proteases
2564 Inhibition, ETC complexes of the respiratory chain leads to Increase, Mt Dysfunction
2565 Inhibition, ETC complexes of the respiratory chain leads to Increase, Oxidative Stress
2821 Inhibition, ETC complexes of the respiratory chain leads to N/A, Mitochondrial dysfunction 1
2636 Inhibition, ETC complexes of the respiratory chain leads to Decrease, MMP
123 Reduction, Eggshell thickness leads to N/A, Reproductive failure
125 Impairment, Endothelial network leads to Insufficiency, Vascular
976 Impairment, Endothelial network leads to Altered, Cardiovascular development/function
126 Agonism, Estrogen receptor leads to Altered, Reproductive behaviour
127 Agonism, Estrogen receptor leads to Impaired development of, Reproductive organs
128 Agonism, Estrogen receptor leads to Increase, Vitellogenin synthesis in liver
2613 Antagonism, Estrogen receptor leads to EMT
129 Antagonism, Estrogen receptor leads to Reduction, Vitellogenin synthesis in liver
132 Increase, FA Influx leads to Accumulation, Triglyceride
133 Activation, FAS leads to Synthesis, De Novo FA
1422 Activation, FAS leads to Increased, lipogenesis
136 N/A, Gap leads to Reduction, Ca and HCO3 transport to shell gland
2077 Activation, Glucocorticoid Receptor leads to Increase, Cripto-1 expression
385 Activation, Glucocorticoid Receptor leads to Induction, IKB inhibitory protein
1451 Activation, Glucocorticoid Receptor leads to Reduced, BDNF
2261 Activation, Glucocorticoid Receptor leads to Up Regulation, CD36
2266 Activation, Glucocorticoid Receptor leads to Decrease, ACAD
2039 Activation, Glucocorticoid Receptor leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
2041 Activation, Glucocorticoid Receptor leads to Decreased, PPAR-alpha activation
143 Reduction, Gonadotropins, circulating concentrations leads to Reduction, Testosterone synthesis by ovarian theca cells
2878 Depletion, GSH leads to Increased, Reactive oxygen species
144 Depletion, GSH leads to N/A, Oxidative stress
146 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) leads to Peptide Oxidation
147 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) leads to Up Regulation, TGFbeta1 expression
996 N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects leads to Alterations, Cellular proliferation / hyperplasia
154 Decreased, HSD17B10 expression leads to Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity
158 Hyperplasia, Hyperplasia leads to Promotion, Hepatocelluar carcinoma
386 Induction, IKB inhibitory protein leads to Inhibition, Nuclear factor kappa B (NF-kB)
159 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 leads to Induction, Sustained Hepatotoxicity
781 Increase, Inflammation leads to Increase, Regenerative cell proliferation (forestomach epithelial cells)
2573 Increase, Inflammation leads to Increased, Invasion
2574 Increase, Inflammation leads to Increase, angiogenesis
1839 Increase, Inflammation leads to Fibroproliferative airway lesions
2976 Increase, Inflammation leads to General Apoptosis
929 Increase, Inflammation leads to Cholestasis, Pathology
1722 Increase, Inflammation leads to Expression of Collagen
1724 Increase, Inflammation leads to EMT
1699 Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways leads to Activation, Dendritic Cells
388 Suppression, Inflammatory cytokines leads to Decreased, Lymphocytes
2817 Inadequate DNA repair leads to Cataracts
1910 Inadequate DNA repair leads to Increase, DNA strand breaks
1912 Inadequate DNA repair leads to Increase, Chromosomal aberrations
164 Inadequate DNA repair leads to Increase, Mutations
168 N/A, Interferences with SH-/selen-proteins leads to Depletion, GSH
169 Increase, Liver and splenic hemosiderosis leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
170 Induction, Liver “Dysfunctional” Changes by CGA 330050 leads to Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307
874 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Changes/Inhibition, Cellular Homeostasis and Apoptosis
875 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Alterations, Cellular proliferation / hyperplasia
876 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Formation, Hepatocellular and Bile duct tumors
172 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
516 Activation, LXR leads to Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)
173 Activation, LXR leads to Up Regulation, CD36
174 Activation, LXR leads to Activation, ChREBP
175 Activation, LXR leads to Activation, FAS
176 Activation, LXR leads to Activation, SCD-1
177 Activation, LXR leads to Activation, SREBP-1c
479 Activation, LXR leads to Activation, SREBF1
490 Activation, LXR leads to Up Regulation, FAS
491 Activation, LXR leads to Up Regulation, SCD-1
510 Activation, LXR leads to Inhibition, PPAR alpha
389 Decreased, Lymphocytes leads to Increased, Disease susceptibility
390 Decreased, Lymphocytes leads to Suppression, Immune system
182 N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number leads to N/A, Cyanosis occurs
1367 Damaging, Mitochondria leads to Apoptosis
2822 N/A, Mitochondrial dysfunction 1 leads to Decrease, Mitochondrial ATP production
1311 N/A, Mitochondrial dysfunction 1 leads to Altered, Ca2+-calmodulin activated signal transduction
582 N/A, Mitochondrial dysfunction 1 leads to Neuronal network function, Decreased
363 N/A, Mitochondrial dysfunction 1 leads to Cell injury/death
1152 N/A, Mitochondrial dysfunction 1 leads to impaired, Hive thermoregulation
1154 N/A, Mitochondrial dysfunction 1 leads to Weakened, Colony
904 N/A, Mitochondrial dysfunction 1 leads to Impaired, Proteostasis
908 N/A, Mitochondrial dysfunction 1 leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
660 N/A, Mitochondrial dysfunction 1 leads to Overwhelmed, Mitochondrial DNA repair mechanisms
1684 N/A, Mitochondrial dysfunction 1 leads to Oxidative Stress
664 N/A, Mitochondrial dysfunction 1 leads to impaired, Thoracic shivering
1958 N/A, Mitochondrial dysfunction 1 leads to Increased reactive oxygen species (in the mitochondria)
2224 N/A, Mitochondrial dysfunction 1 leads to Increase, ROS production
2227 N/A, Mitochondrial dysfunction 1 leads to Increase, ROS
2228 N/A, Mitochondrial dysfunction 1 leads to Decrease, ATP pool
188 Disruption, Mitochondrial electron transport chain leads to Decrease, Mitochondrial ATP production
189 Disruption, Mitochondrial electron transport chain leads to Increase, ROS production
617 Decreased, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis
2931 Decreased, Mitochondrial fatty acid beta-oxidation leads to Mitochondrial dysfunction
190 Decreased, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid
1025 Abnormal, Morphogenesis leads to Increased, Developmental Defects
196 Abnormal, Morphogenesis leads to Increased, Lethality
197 Abnormal, Morphogenesis leads to Increased, Structural malformations
2609 Increase, Mutations leads to Increase,miRNA levels
1896 Increase, Mutations leads to Increase, Cell Proliferation (Epithelial Cells)
899 Increase, Mutations leads to Increase, Cancer
1978 Increase, Mutations leads to Increase, Cell Proliferation
1984 Increase, Mutations leads to Increase, lung cancer
202 Increase, Mutations leads to Increase, Heritable mutations in offspring
203 Altered, Neuroanatomy leads to Altered, Neurophysiology
906 Neuroinflammation leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
1687 Neuroinflammation leads to Cell injury/death
2717 Neuroinflammation leads to Increase, Cell death
2500 Neuroinflammation leads to Neuronal network function, Decreased
208 Neuroinflammation leads to N/A, Neurodegeneration
2288 Neuroinflammation leads to Encephalitis
759 Neuroinflammation leads to Synaptogenesis, Decreased
2941 Neuronal dysfunction leads to Neurological disorder
210 Neuronal dysfunction leads to Neuroinflammation
384 Altered, Neurophysiology leads to Cognitive Function, Decreased
212 Decreased, Nitric Oxide leads to Decreased, Long-term potentiation (LTP)
213 Inhibition, NMDARs leads to Decreased, Calcium influx
214 Inhibition, NMDARs leads to Impairment, Learning and memory
215 Inhibition, NMDARs leads to Neuronal dysfunction
228 Binding of antagonist, NMDA receptors leads to Impairment, Learning and memory
229 Binding of antagonist, NMDA receptors leads to Inhibition, NMDARs
2306 Inhibition, Nuclear factor kappa B (NF-kB) leads to Increased proinflammatory mediators
1828 Inhibition, Nuclear factor kappa B (NF-kB) leads to Activation, Caspase 8 pathway
1871 Inhibition, Nuclear factor kappa B (NF-kB) leads to Impairment of TDAR
2644 Inhibition, Nuclear factor kappa B (NF-kB) leads to Increase in inflammation
1921 Inhibition, Nuclear factor kappa B (NF-kB) leads to Impaired T cell activation
387 Inhibition, Nuclear factor kappa B (NF-kB) leads to Suppression, Inflammatory cytokines
2003 Inhibition, Nuclear factor kappa B (NF-kB) leads to Suppression of T cell activation
1379 Peptide Oxidation leads to Activation, JNK
922 Peptide Oxidation leads to N/A, Mitochondrial dysfunction 1
923 Peptide Oxidation leads to Release, Cytokine
1698 Peptide Oxidation leads to S-Glutathionylation, eNOS
932 Peptide Oxidation leads to Cholestasis, Pathology
948 Peptide Oxidation leads to Oxidation, Glutathione
1467 Peptide Oxidation leads to Increase, DNA Damage
980 Peptide Oxidation leads to Decrease, GTPCH-1
1237 Peptide Oxidation leads to Increased activation, Nuclear factor kappa B (NF-kB)
992 Peptide Oxidation leads to Decrease, AKT/eNOS activity
236 Peptide Oxidation leads to Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
764 Peptide Oxidation leads to Increase, hepatocellular adenomas and carcinomas
765 Peptide Oxidation leads to Increase, Cytotoxicity
239 N/A, Oxidative stress leads to Neuronal dysfunction
240 Propagation, Oxidative stress leads to Down Regulation, Gulcose-6-phosphate dehydrogenase
241 Propagation, Oxidative stress leads to Damaging, Red blood cells; hemolysis
242 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Altered regulation, Alpha hemoglobin
243 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Formation, Formation of hemoglobin adducts
244 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Propagation, Oxidative stress
245 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Damaging, Red blood cells; hemolysis
928 Bile accumulation, Pathological condition leads to Release, Cytokine
930 Bile accumulation, Pathological condition leads to Production, Reactive oxygen species
248 Bile accumulation, Pathological condition leads to Activation of specific nuclear receptors, Transcriptional change
503 Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) leads to Accumulation, Fatty acid
1386 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Plasma vitellogenin concentrations
2922 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, the ratio of E2/11-KT in plasma
392 Reduction, Plasma 17beta-estradiol concentrations leads to irregularities, ovarian cycle
252 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Vitellogenin synthesis in liver
253 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
254 Increase, Plasma vitellogenin concentrations leads to Increase, Renal pathology due to VTG deposition
1882 Reduction, Plasma vitellogenin concentrations leads to Reduction, egg production and spawning
1769 Reduction, Plasma vitellogenin concentrations leads to Reduction, Cumulative fecundity and spawning
255 Reduction, Plasma vitellogenin concentrations leads to Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
535 Activation, PPARα leads to Activation, LXR alpha
2073 Activation, PPARα leads to Decreased, cholesterol
2134 Activation, PPARα leads to Decreased, 11KT
369 Activation, PPARα leads to Decrease, Steroidogenic acute regulatory protein (STAR)
370 Activation, PPARα leads to Decrease, Translocator protein (TSPO)
1410 Activation, PPARα leads to Activation, HSD17B4
2252 Activation, PPARα leads to Increase, cell proliferation (hepatocytes)
1229 Activation, PPARα leads to Increase, Phenotypic enzyme activity
2253 Activation, PPARα leads to Increase, hepatocellular adenomas and carcinomas
1233 Activation, PPARα leads to Increase, Genes involved in fatty acid oxidation
1236 Activation, PPARα leads to Activation, NADPH Oxidase
256 demethylation, PPARg promoter leads to Decrease, Aromatase (Cyp19a1)
1608 demethylation, PPARg promoter leads to Activation of specific nuclear receptors, PPAR-gamma activation
1402 demethylation, PPARg promoter leads to Activation, SREBP-1
1659 demethylation, PPARg promoter leads to Increased, FA Influx
395 demethylation, PPARg promoter leads to reduction in ovarian granulosa cells, Aromatase (Cyp19a1)
1424 demethylation, PPARg promoter leads to Activation, FAS
411 demethylation, PPARg promoter leads to Up Regulation, CD36
2988 demethylation, PPARg promoter leads to Activation of PPAR
487 demethylation, PPARg promoter leads to Activation, SREBF1
257 Decreased, PPAR-alpha activation leads to Decreased, HSD17B10 expression
2042 Decreased, PPAR-alpha activation leads to Increased, Liver Steatosis
259 Decreased, PPAR-beta activation leads to Decreased, HSD17B10 expression
260 Decreased, PPAR-gamma activation leads to Decreased, HSD17B10 expression
261 Induction, Pre-mature molting leads to Decrease, Fecundity
262 Induction, Pre-mature molting leads to Increase, Mortality
263 Induction, Pre-mature molting leads to Increased Mortality
2482 Activation, Pregnane-X receptor, NR1l2 leads to Induction, Upregulation of glucuronyltransferase activity
266 Feminisation or incomplete development, Primary and accessory male sex organs leads to N/A, Impairment of reproductive capacity
268 Reduction, Prostaglandin E2 concentration leads to N/A, Gap
269 Alkylation, Protein leads to Cell injury/death
271 Alkylation, Protein leads to Peptide Oxidation
1680 Alkylation, Protein leads to Dysfunction, Mitochondria
518 Activation, PXR/SXR leads to Inhibition, FoxA2
526 Activation, PXR/SXR leads to Up Regulation, SCD-1
529 Activation, PXR/SXR leads to Up Regulation, CD36
272 Increase, RBC congestion in liver leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
276 Production, Reactive oxygen species leads to Peptide Oxidation
931 Production, Reactive oxygen species leads to Cholestasis, Pathology
277 Damaging, Red blood cells; hemolysis leads to Increase, Liver and splenic hemosiderosis
278 Damaging, Red blood cells; hemolysis leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
279 Damaging, Red blood cells; hemolysis leads to Increase, RBC congestion in liver
280 Increase, Renal pathology due to VTG deposition leads to Altered, Larval development
2305 Increase, ROS production leads to Inhibition, Nuclear factor kappa B (NF-kB)
2308 Increase, ROS production leads to Increased activation, Nuclear factor kappa B (NF-kB)
282 Increase, ROS production leads to Decreased, Nitric Oxide
283 Increase, ROS production leads to Increased, Oxidative damage
2590 Increase, ROS production leads to Increase, Oxidative DNA damage
2089 Increase, ROS production leads to Increase, Protein oxidation
2348 Increase, ROS production leads to D1 protein deactivation
2093 Increase, ROS production leads to Decrease, MMP
2099 Increase, ROS production leads to Increase,Oxidative DNA damage
1602 Increase, ROS production leads to Increase, DNA Damage
1603 Increase, ROS production leads to Increased, LPO
1623 Increase, ROS production leads to Increased, secretion of local growth factors
2187 Increase, ROS production leads to Increase, Apoptosis
912 Increase, ROS production leads to N/A, Mitochondrial dysfunction 1
2225 Increase, ROS production leads to Increase, Global methylation
2998 Increase, ROS production leads to Increase, Oxidative Stress
1754 Increase, ROS production leads to Decrease, Coupling of OXPHOS
284 Activation, SCD-1 leads to Synthesis, De Novo FA
1404 Activation, SCD-1 leads to Increased, lipogenesis
287 Binding, SH-/selen-proteins leads to N/A, Interferences with SH-/selen-proteins
294 Activation, SREBP-1c leads to Synthesis, De Novo FA
295 Activation, Stellate cells leads to Accumulation, Collagen
2892 Activation, Stellate cells leads to Increased extracellular matrix deposition
436 Decrease, Steroidogenic acute regulatory protein (STAR) leads to Reduction, Cholesterol transport in mitochondria
298 Induction, Sustained Cell Proliferation leads to Formation, Liver tumor
299 Induction, Sustained Hepatotoxicity leads to Induction, Sustained Cell Proliferation
301 Activation/Proliferation, T-cells leads to N/A, Allergic contact dermatitis on challenge
835 Activation/Proliferation, T-cells leads to sensitisation, skin
1701 Activation/Proliferation, T-cells leads to Increase, Allergic Respiratory Hypersensitivity Response
302 Reduction, Testosterone synthesis by ovarian theca cells leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
303 Up Regulation, TGFbeta1 expression leads to Accumulation, Collagen
304 Up Regulation, TGFbeta1 expression leads to Activation, Stellate cells
810 TH synthesis, Decreased leads to Increased, Serum creatinine
305 TH synthesis, Decreased leads to T4 in serum, Decreased
1504 TH synthesis, Decreased leads to BDNF, Reduced
1505 TH synthesis, Decreased leads to GABAergic interneurons, Decreased
1506 TH synthesis, Decreased leads to Impairment, Learning and memory
1768 TH synthesis, Decreased leads to Reduction, Plasma 17beta-estradiol concentrations
1040 Thyroperoxidase, Inhibition leads to Reduced, Anterior swim bladder inflation
790 Thyroperoxidase, Inhibition leads to Decrease, Incorporation of active iodide into iodotyrosines
309 Thyroperoxidase, Inhibition leads to TH synthesis, Decreased
366 Thyroperoxidase, Inhibition leads to T4 in serum, Decreased
383 Thyroperoxidase, Inhibition leads to Cognitive Function, Decreased
444 T4 in neuronal tissue, Decreased leads to BDNF, Reduced
746 T4 in neuronal tissue, Decreased leads to Hippocampal gene expression, Altered
1039 T4 in serum, Decreased leads to Reduced, Anterior swim bladder inflation
2865 T4 in serum, Decreased leads to Insulin resistance, increased
312 T4 in serum, Decreased leads to T4 in neuronal tissue, Decreased
1387 T4 in serum, Decreased leads to Hippocampal gene expression, Altered
1388 T4 in serum, Decreased leads to Hippocampal anatomy, Altered
1389 T4 in serum, Decreased leads to Hippocampal Physiology, Altered
2420 T4 in serum, Decreased leads to Increase, Thyroid-stimulating hormone (TSH)
2422 T4 in serum, Decreased leads to Increased, Thyroid-stimulating hormone (TSH)
1143 T4 in serum, Decreased leads to Decreased, Thyroxine (T4) in tissues
2168 T4 in serum, Decreased leads to Altered, Amphibian metamorphosis
403 T4 in serum, Decreased leads to Cognitive Function, Decreased
2473 T4 in serum, Decreased leads to Occurrence, Cytoplasmic vacuolization (Renal tubule)
2474 T4 in serum, Decreased leads to Occurrence, Cystic dilatation (renal tubule)
2475 T4 in serum, Decreased leads to Occurrence, Cytoplasmic vacuolization (podocyte)
2038 T4 in serum, Decreased leads to Decreased, Triiodothyronine (T3)
315 Reduction, Vitellogenin synthesis in liver leads to Reduction, Plasma vitellogenin concentrations
316 Altered, Transcription of genes by AR leads to Feminisation or incomplete development, Primary and accessory male sex organs
317 Altered, Transcription of genes by AR leads to Alteration, Wnt pathway
2127 Altered, Transcription of genes by AR leads to AGD, decreased
2132 Altered, Transcription of genes by AR leads to nipple retention, increased
2909 Altered, Transcription of genes by AR leads to Increase, Androgen receptor
2273 Altered, Transcription of genes by AR leads to Reduced granulosa cell proliferation
319 Activation of specific nuclear receptors, Transcriptional change leads to Cholestasis, Pathology
399 Decrease, Translocator protein (TSPO) leads to Reduction, Testosterone synthesis in Leydig cells
437 Decrease, Translocator protein (TSPO) leads to Reduction, Cholesterol transport in mitochondria
321 Accumulation, Triglyceride leads to Damaging, Mitochondria
2265 Accumulation, Triglyceride leads to Increased, Liver Steatosis
474 Accumulation, Triglyceride leads to Accumulation, Liver lipid
324 N/A, Unknown leads to Proliferation, Cell proliferation in the absence of cytotoxicity
751 N/A, Unknown leads to Increased, Kidney Failure
2884 Induction, Upregulation of glucuronyltransferase activity leads to Increase, Glucuronidation of T4
2428 Induction, Upregulation of glucuronyltransferase activity leads to Increased, T4/T3 catabolism
2478 Induction, Upregulation of glucuronyltransferase activity leads to Increased, Clearance of thyroxine from serum
2483 Induction, Upregulation of glucuronyltransferase activity leads to T4 in serum, Decreased
2235 Induction, Upregulation of glucuronyltransferase activity leads to Increase, Biliary excretion TH glucuronide
1036 Insufficiency, Vascular leads to Increased, Developmental Defects
329 Insufficiency, Vascular leads to Abnormal, Morphogenesis
330 Binding, VEGF-A leads to Decreased, VegfR2
331 Binding, VEGF-A leads to Inhibition, VegfR2
332 Production, VEGF-A leads to Binding, VEGF-A
333 Production, VEGF-A leads to Decreased, VegfR2
334 Decreased, VegfR2 leads to Inhibition, VegfR2
335 Inhibition, VegfR2 leads to Reduction, Angiogenesis
336 Increase, Vitellogenin synthesis in liver leads to Increase, Plasma vitellogenin concentrations
337 Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development leads to Reduction, Cumulative fecundity and spawning
338 Alteration, Wnt pathway leads to Feminisation or incomplete development, Primary and accessory male sex organs
1567 Altered, Cardiovascular development/function leads to Increase, Early Life Stage Mortality
1352 Altered, Cardiovascular development/function leads to Increase, Mortality
977 Altered, Cardiovascular development/function leads to Increase, Pericardial edema
514 Accumulation, Fatty acid leads to Increased, Triglyceride formation
515 Accumulation, Fatty acid leads to Increased, Liver Steatosis
472 Accumulation, Fatty acid leads to Accumulation, Triglyceride
502 Accumulation, Fatty acid leads to Accumulation, Liver lipid
2621 Decrease, Fecundity leads to Decrease, Reproduction
1886 Decrease, Fecundity leads to Decrease, Population growth rate
135 Decrease, Fecundity leads to Decline, Population
1472 Decrease, Fertility leads to Decrease, Population growth rate
564 Impairment, Learning and memory leads to Abnormal, Roll change within caste
2872 Impairment, Learning and memory leads to decreased, IQ
583 Impairment, Learning and memory leads to Abnormal, Foraging activity and behavior
1644 Impairment, Learning and memory leads to Decreased, locomotion
2889 N/A, Liver Steatosis leads to Cell injury/death
405 Malformation, Male reproductive tract leads to impaired, Fertility
2463 Increase, Mortality leads to Decrease, Population growth rate
198 Increase, Mortality leads to Decrease, Fecundity
199 Increase, Mortality leads to Decline, Population
1004 Increase, Mortality leads to Decreased, population 1
1013 Increase, Mortality leads to Decreased, Population size
1191 Increased Mortality leads to Decreased, Population size
428 Increased Mortality leads to Decreased, Population trajectory
2486 Increased Mortality leads to Decline, Population trajectory
200 Increased Mortality leads to Decline, Population
2013 Increased Mortality leads to Decrease, Population growth rate
756 Increased Mortality leads to Decreased, population 1
1069 N/A, Neurodegeneration leads to Impairment, Learning and memory
368 N/A, Neurodegeneration leads to Neuronal network function, Decreased
647 N/A, Neurodegeneration leads to Decreased, Neuronal network function in adult brain
207 N/A, Neurodegeneration leads to Neuroinflammation
2287 N/A, Neurodegeneration leads to Encephalitis
1265 Decline, Population leads to Alteration, Food-web structures
296 Increased, Structural malformations leads to Increased, Lethality
548 Formation, Pro-mutagenic DNA Adducts leads to Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts
551 Formation, Pro-mutagenic DNA Adducts leads to Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
344 Formation, Pro-mutagenic DNA Adducts leads to Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
345 Formation, Pro-mutagenic DNA Adducts leads to Tumorigenesis, Hepatocellular carcinoma
352 Formation, Pro-mutagenic DNA Adducts leads to Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
549 Increased, Induced Mutations in Critical Genes leads to Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
342 Increased, Induced Mutations in Critical Genes leads to Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
346 Increased, Induced Mutations in Critical Genes leads to Tumorigenesis, Hepatocellular carcinoma
351 Increased, Induced Mutations in Critical Genes leads to Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
891 Increased, Induced Mutations in Critical Genes leads to Increase, Site of Contact Nasal Tumors
343 Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H leads to Tumorigenesis, Hepatocellular carcinoma
340 Activation, Pre-MIE: Metabolism of AFB1 leads to Formation, Pro-mutagenic DNA Adducts
348 BDNF, Reduced leads to Aberrant, Dendritic morphology
353 BDNF, Reduced leads to Cell injury/death
354 BDNF, Reduced leads to Reduced, Presynaptic release of glutamate
870 BDNF, Reduced leads to GABAergic interneurons, Decreased
445 BDNF, Reduced leads to Down Regulation, K-Cl co-transporter 2 (KCC2)
448 BDNF, Reduced leads to Synaptogenesis, Decreased
1507 BDNF, Reduced leads to Impairment, Learning and memory
356 Aberrant, Dendritic morphology leads to Synaptogenesis, Decreased
357 Reduced, Presynaptic release of glutamate leads to Synaptogenesis, Decreased
350 Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci leads to Tumorigenesis, Hepatocellular carcinoma
358 Synaptogenesis, Decreased leads to Neuronal network function, Decreased
656 Synaptogenesis, Decreased leads to Neuroinflammation
359 Neuronal network function, Decreased leads to Impairment, Learning and memory
2411 Neuronal network function, Decreased leads to Cognitive Function, Decreased
2953 Neuronal network function, Decreased leads to Neurological disorder
2501 Neuronal network function, Decreased leads to Memory Loss
360 Binding of agonist, NMDARs leads to Overactivation, NMDARs
361 Overactivation, NMDARs leads to Increased, Intracellular Calcium overload
2781 Overactivation, NMDARs leads to Status epilepticus
3038 Overactivation, NMDARs leads to Increase, Cell membrane depolarization
2806 Overactivation, NMDARs leads to Loss of drebrin
1860 Increased, Intracellular Calcium overload leads to Occurrence, Epileptic seizure
1862 Increased, Intracellular Calcium overload leads to Cell injury/death
2140 Increased, Intracellular Calcium overload leads to Status epilepticus
362 Increased, Intracellular Calcium overload leads to N/A, Mitochondrial dysfunction 1
892 Increased, Intracellular Calcium overload leads to Decreased, Neuronal network function in adult brain
2704 Increased, Intracellular Calcium overload leads to Activation, calpain
2709 Increased, Intracellular Calcium overload leads to Decrease, OXPHOS
2710 Increased, Intracellular Calcium overload leads to Endoplasmic reticulum stress
3042 Increased, Intracellular Calcium overload leads to Mitochondrial dysfunction
833 Covalent Binding, Protein leads to Activation, Keratinocytes
2649 Covalent Binding, Protein leads to Increased proinflammatory mediators
2650 Covalent Binding, Protein leads to Increase, Allergic Respiratory Hypersensitivity Response
376 Covalent Binding, Protein leads to Response, Keratinocytes
377 Covalent Binding, Protein leads to Activation, Dendritic Cells
2202 Covalent Binding, Protein leads to Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways
378 Response, Keratinocytes leads to Activation, Dendritic Cells
380 Response, Keratinocytes leads to Activation/Proliferation, T-cells
379 Activation, Dendritic Cells leads to Activation/Proliferation, T-cells
2236 Increase, Biliary excretion TH glucuronide leads to T4 in serum, Decreased
570 Suppression, Immune system leads to Increased, Viral susceptibility
393 irregularities, ovarian cycle leads to Decrease, Fertility
394 irregularities, ovarian cycle leads to impaired, Fertility
2387 impaired, Fertility leads to Decrease of egg production and cummulative fecundity
2292 impaired, Fertility leads to Decrease, Population growth rate
396 reduction in ovarian granulosa cells, Aromatase (Cyp19a1) leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
402 Metabolism of AFB1, Production of Reactive Electrophiles leads to Formation, Pro-mutagenic DNA Adducts
2125 Reduction, Testosterone synthesis in Leydig cells leads to Decrease, testosterone levels
439 Reduction, Testosterone synthesis in Leydig cells leads to Reduction of testosterone
461 Increase, Luteinizing hormone (LH) leads to Increase proliferation, Leydig cell
462 Hyperplasia, Leydig cell leads to impaired, Fertility
398 Increase proliferation, Leydig cell leads to Hyperplasia, Leydig cell
552 Inhibition, Na+/I- symporter (NIS) leads to TH synthesis, Decreased
2232 Inhibition, Na+/I- symporter (NIS) leads to T4 in serum, Decreased
442 Inhibition, Na+/I- symporter (NIS) leads to Thyroidal Iodide, Decreased
1503 Inhibition, Na+/I- symporter (NIS) leads to Impairment, Learning and memory
872 Thyroidal Iodide, Decreased leads to TH synthesis, Decreased
443 Thyroidal Iodide, Decreased leads to T4 in serum, Decreased
446 Down Regulation, K-Cl co-transporter 2 (KCC2) leads to Delay, Developmental GABA shift
447 Delay, Developmental GABA shift leads to Synaptogenesis, Decreased
1491 Decreased, Population trajectory leads to Increased Mortality
591 Increased, Atrioventricular block and bradycardia leads to Respiratory distress/arrest
432 Increased, Atrioventricular block and bradycardia leads to Increased Mortality
592 Respiratory distress/arrest leads to N/A, hypoxia
433 Respiratory distress/arrest leads to Increased Mortality
608 Reduction of testosterone leads to Malformation, Male reproductive tract
1649 Reduction of testosterone leads to Decreased sperm quantity or quality in the adult, Decreased fertility
460 Reduction of testosterone leads to Increase, Luteinizing hormone (LH)
438 Reduction, Cholesterol transport in mitochondria leads to Reduction, Testosterone synthesis in Leydig cells
471 Suppression, VLDL secretion leads to Accumulation, Liver lipid
538 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis
470 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Liver lipid
475 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid
486 Increased, Triglyceride formation leads to Increased, Liver Steatosis
476 Suppression, Constitutive androstane receptor, NR1l3 leads to Activation, LXR
477 Suppression, Constitutive androstane receptor, NR1l3 leads to demethylation, PPARg promoter
1662 Activation, SREBF1 leads to Increased, Liver Steatosis
482 Activation, SREBF1 leads to Increased, De Novo FA synthesis
489 Activation, SREBF1 leads to Up Regulation, SCD-1
512 Increased, De Novo FA synthesis leads to Accumulation, Fatty acid
1607 Increased, De Novo FA synthesis leads to Increased, Liver Steatosis
484 Increased, De Novo FA synthesis leads to Increased, Triglyceride formation
1695 Increased, Liver Steatosis leads to Increased, Reactive oxygen species
2263 Increased, Fatty acid uptake leads to Increased, Liver Steatosis
1657 Up Regulation, SCD-1 leads to Accumulation, Triglyceride
493 Up Regulation, SCD-1 leads to Increased, Triglyceride formation
492 Up Regulation, FAS leads to Increased, De Novo FA synthesis
1658 Increased, FA Influx leads to Increased, Triglyceride formation
504 Increased, FA Influx leads to Accumulation, Triglyceride
505 Increased, FA Influx leads to Accumulation, Fatty acid
507 Up Regulation, LDLR (low density lipoprotein receptor) leads to Increased, LDL uptake
508 Increased, LDL uptake leads to Accumulation, Fatty acid
511 Inhibition, PPAR alpha leads to Inhibition, Mitochondrial fatty acid beta-oxidation
517 Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) leads to Increased, De Novo FA synthesis
519 Inhibition, FoxA2 leads to Down Regulation, CPT1A
523 Inhibition, FoxA2 leads to Down Regulation, HMGCS2
520 Down Regulation, CPT1A leads to Decreased, Mitochondrial fatty acid beta-oxidation
524 Down Regulation, HMGCS2 leads to Decreased, Ketogenesis
1660 Decreased, Ketogenesis leads to Accumulation, Fatty acid
532 Activation, NRF2 leads to Activation, NR1H4
1406 Activation, NRF2 leads to Activation, FXR
533 Activation, NR1H4 leads to Activation, SHP
534 Activation, NR1H4 leads to Activation, PPARα
896 Activation, SHP leads to Inhibition, SREBP1c
1409 Activation, SHP leads to Activation, PPARα
1412 Activation, SHP leads to Inhibition, LXR
1414 Activation, SHP leads to Inhibition, LRH-1
537 Decreased, DHB4/HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation
1606 Activation, LXR alpha leads to Increased, De Novo FA synthesis
1661 Activation, AKT2 leads to Activation, SREBF1
541 inflammation leads to Activation, AKT2
544 Decrease, Ovulation leads to Reduction, Cumulative fecundity and spawning
687 Decrease, Ovulation leads to Reduced, Reproductive Success
1471 Decrease, Ovulation leads to Decrease, Fertility
1753 Decrease, Ovulation leads to Decrease, Fecundity
550 Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) leads to Tumorigenesis, Hepatocellular carcinoma
547 Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts leads to Increased, Induced Mutations in Critical Genes
1645 GR Agonist, Activation leads to Decreased Leydig Cells
1646 GR Agonist, Activation leads to Repressed expression of steroidogenic enzymes
1648 Repressed expression of steroidogenic enzymes leads to Reduction, Testosterone synthesis in Leydig cells
1647 Decreased Leydig Cells leads to Reduction, Testosterone synthesis in Leydig cells
1650 Decreased sperm quantity or quality in the adult, Decreased fertility leads to impaired, Fertility
581 Activation, Nicotinic acetylcholine receptor leads to N/A, Mitochondrial dysfunction 1
1146 Activation, Nicotinic acetylcholine receptor leads to Impairment, Learning and memory
1147 Activation, Nicotinic acetylcholine receptor leads to Abnormal, Foraging activity and behavior
658 Activation, Nicotinic acetylcholine receptor leads to Desensitization, Nicotinic acetylcholine receptor
569 Abnormal, Foraging activity and behavior leads to Decrease, Number of worker bees
584 Abnormal, Foraging activity and behavior leads to Reduced, Food storage
1144 Abnormal, Foraging activity and behavior leads to Weakened, Colony
1148 Abnormal, Foraging activity and behavior leads to Abnormal, Roll change within caste
1150 Abnormal, Foraging activity and behavior leads to Abnormal, Role change within caste
558 Reduced, Food storage leads to Decrease, Number of worker bees
562 Reduced, Food storage leads to impaired, Larval development
565 Abnormal, Roll change within caste leads to Reduced, Brood care
579 Abnormal, Roll change within caste leads to Reduced, Food storage
580 Abnormal, Roll change within caste leads to Decrease, Number of worker bees
1149 Abnormal, Roll change within caste leads to Weakened, Colony
566 Reduced, Brood care leads to impaired, Larval development
563 impaired, Larval development leads to Death/Failure, Colony
574 impaired, Hive thermoregulation leads to Death/Failure, Colony
1153 impaired, Hive thermoregulation leads to Weakened, Colony
662 Accumulation, Damaged mitochondrial DNA leads to Accelerated, Aging
663 Accelerated, Aging leads to Decrease, Number of worker bees
559 Decrease, Number of worker bees leads to Death/Failure, Colony
573 Decrease, Number of worker bees leads to impaired, Hive thermoregulation
567 Increase, Energetic demands and therefore metabolic stress leads to Increased, Appetite and hunger
568 Increased, Appetite and hunger leads to Abnormal, Foraging activity and behavior
571 Increased, Viral susceptibility leads to impaired, Development
575 Increased, Viral susceptibility leads to Abnormal, Foraging activity and behavior
572 impaired, Development leads to Decrease, Number of worker bees
576 Decreased, Glucose oxidase enzyme activity leads to Decreased, Hydrogen peroxide production
577 Decreased, Hydrogen peroxide production leads to Reduced, Antiseptic incorporated in food
578 Reduced, Antiseptic incorporated in food leads to Abnormal, Roll change within caste
665 impaired, Thoracic shivering leads to impaired, Hive thermoregulation
585 Inhibition, sodium channel leads to Decreased, Sodium conductance 1
590 Inhibition, sodium channel leads to Increased, Atrioventricular block and bradycardia
1242 Inhibition, sodium channel leads to Decreased, sodium conductance 2
586 Decreased, Sodium conductance 1 leads to Reduced, swimming speed
594 Decreased, Sodium conductance 1 leads to Increased, Atrioventricular block and bradycardia
587 Reduced, swimming speed leads to Reduced, feeding 1
588 Reduced, swimming speed leads to Increased, predation
589 Reduced, feeding 1 leads to Increased, predation
596 Reduced, feeding 1 leads to Reduced, survival
595 Increased, predation leads to Reduced, survival
654 Increased, predation leads to Decreased, survival
593 N/A, hypoxia leads to Increased, amputations
597 Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel leads to Decreased, Sodium conductance 1
603 modulation, sodium channel leads to prolonged, Depolarization of neuronal membrane
604 prolonged, Depolarization of neuronal membrane leads to Overactivation, Neuronotransmitter release
605 Overactivation, Neuronotransmitter release leads to Overactivation, muscle contraction
606 Overactivation, muscle contraction leads to Increased, Ataxia, paralysis, or hyperactivity
607 Increased, Ataxia, paralysis, or hyperactivity leads to Increased Mortality
1861 Occurrence, Epileptic seizure leads to Increased, glutamate
1999 Occurrence, Epileptic seizure leads to Overactivation, NMDARs
630 Occurrence, A paroxysmal depolarizing shift leads to Occurrence, Epileptic seizure
2656 Decreased, Neuronal network function in adult brain leads to Sensory axonal peripheral neuropathy
634 Decreased, Neuronal network function in adult brain leads to Impairment, Learning and memory
1316 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, muscular waves in foot
1317 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, valve movement
1318 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increase, cilia movement
1319 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to increased mantel display
1337 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, oocyte maturation
635 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, serotonin (5-HT) 1
643 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, serotonin (5-HT)
1208 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, cilia movement
636 Increased, serotonin (5-HT) 1 leads to Increase, cilia movement
640 Increased, serotonin (5-HT) 1 leads to Increased, muscular waves in foot
1172 Increased, serotonin (5-HT) 1 leads to Increased, valve movement
1186 Increased, serotonin (5-HT) 1 leads to Decreased, gametogenesis
1189 Increased, serotonin (5-HT) 1 leads to Increased, locomotion
1192 Increased, serotonin (5-HT) 1 leads to increased or inappropriate, mantel display
1321 Increase, cilia movement leads to induced spawning
1335 Increase, cilia movement leads to Induced parturition
637 Increase, cilia movement leads to Increased, locomotion
639 Increase, cilia movement leads to Increased, foot detachment
1178 Increase, cilia movement leads to premature, spawning 1
1187 Increase, cilia movement leads to premature, Spawning
1217 Increase, cilia movement leads to Increased, water pumping
1218 Increase, cilia movement leads to Depletion, energy reserves
638 Increased, locomotion leads to Increase, predation
1177 Increased, locomotion leads to Depletion, energy reserves
2634 Increase, predation leads to Decrease, Population growth rate
1176 Increased, foot detachment leads to Depletion, energy reserves
1183 Increased, foot detachment leads to Increase, predation
641 Increased, muscular waves in foot leads to Increased, locomotion
642 Increased, muscular waves in foot leads to Increased, foot detachment
1228 Increased, muscular waves in foot leads to Depletion, energy reserves
1327 Increased, serotonin (5-HT) leads to Increased, valve movement
1332 Increased, serotonin (5-HT) leads to Increased, muscular waves in foot
1333 Increased, serotonin (5-HT) leads to Increase, cilia movement
1336 Increased, serotonin (5-HT) leads to increased mantel display
644 Increased, serotonin (5-HT) leads to Decreased, anxiety
1207 Increased, serotonin (5-HT) leads to Increased, mantel display
1209 Increased, serotonin (5-HT) leads to Increased, cilia movement
1212 Increased, serotonin (5-HT) leads to Increased, oocyte maturation
645 Decreased, anxiety leads to Decreased, sheltering
646 Decreased, sheltering leads to Increased, predation
1643 Decrease, histaminergic neuron excitation leads to Impairment, Learning and memory
649 Decrease, histaminergic neuron excitation leads to N/A, sedation
650 N/A, sedation leads to Decreased, locomotion
651 Decreased, locomotion leads to Increased, predation
1061 Antagonism, Histamine Receptor (H2) leads to Decrease, histaminergic neuron excitation
1309 Desensitization, Nicotinic acetylcholine receptor leads to Altered, Ca2+-calmodulin activated signal transduction
659 Desensitization, Nicotinic acetylcholine receptor leads to Neuronal network function, Decreased
661 Overwhelmed, Mitochondrial DNA repair mechanisms leads to Accumulation, Damaged mitochondrial DNA
666 Binding at picrotoxin site, iGABAR chloride channel leads to Reduction, Ionotropic GABA receptor chloride channel conductance
683 Reduction, Neuronal synaptic inhibition leads to Generation, Amplified excitatory postsynaptic potential (EPSP)
672 Reduced, Prostaglandin F2alpha concentration, plasma leads to Reduced, Spawning behavior
678 Reduced, Prostaglandin F2alpha concentration, plasma leads to Reduced, Pheromone release
671 Reduced, Prostaglandin F2alpha synthesis, ovary leads to Reduced, Prostaglandin F2alpha concentration, plasma
673 Reduced, Spawning behavior leads to Reduced, Ability to attract spawning mates
674 Reduced, Ability to attract spawning mates leads to Reduced, Reproductive Success
675 Reduced, Reproductive Success leads to Decrease, Population growth rate
679 Reduced, Pheromone release leads to Reduced, Ability to attract spawning mates
682 Decreased, Prostaglandin F2alpha synthesis, ovary leads to Reduced, Prostaglandin F2alpha concentration, plasma
684 Generation, Amplified excitatory postsynaptic potential (EPSP) leads to Occurrence, A paroxysmal depolarizing shift
685 Reduced, Prostaglandins, ovary leads to Decrease, Ovulation
690 Reduced, Prostaglandin E2 concentration, hypothalamus leads to Reduced, Gonadotropin releasing hormone, hypothalamus
691 Reduced, Gonadotropin releasing hormone, hypothalamus leads to Reduced, Luteinizing hormone (LH), plasma
692 Reduced, Luteinizing hormone (LH), plasma leads to Reduced, Maturation inducing steroid, plasma
693 Reduced, Maturation inducing steroid, plasma leads to Reduced, Maturation inducing steroid receptor signalling, oocyte
694 Reduced, Maturation inducing steroid receptor signalling, oocyte leads to Increased, cyclic adenosine monophosphate
698 Reduced, Maturation inducing steroid receptor signalling, oocyte leads to Upregulated, Spindle assembly checkpoint protein Mad2-oocyte
695 Increased, cyclic adenosine monophosphate leads to Reduced, Reproductive Success
696 Increased, cyclic adenosine monophosphate leads to Reduced, Meiotic prophase I/metaphase I transition, oocyte
697 Reduced, Meiotic prophase I/metaphase I transition, oocyte leads to Reduced, Reproductive Success
699 Upregulated, Spindle assembly checkpoint protein Mad2-oocyte leads to Increased, Chromosome misseggregation
700 Increased, Chromosome misseggregation leads to Reduced, Reproductive Success
701 impaired, ion channels leads to Altered, Action Potential
702 Altered, Action Potential leads to Increased, cardiac arrthymia
703 Increased, cardiac arrthymia leads to Increased Mortality
707 Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) leads to Increase, Cytotoxicity (renal tubular cell)
1676 Increase, Cytotoxicity (renal tubular cell) leads to Occurrence, Kidney toxicity
708 Increase, Cytotoxicity (renal tubular cell) leads to Increase, Regenerative cell proliferation (tubular epithelial cells)
785 Increase, Regenerative cell proliferation (tubular epithelial cells) leads to Increase, Hyperplasia (tubular epithelial cells)
760 Increase, Regenerative cell proliferation (tubular epithelial cells) leads to Increase, Hyperplasia (renal tubular cells)
706 Increased, Binding of chemicals to 2u (serum) leads to Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)
711 Activation, Constitutive androstane receptor leads to Increase, cell proliferation (hepatocytes)
1268 Activation, Constitutive androstane receptor leads to Altered expression of hepatic CAR-dependent genes
773 Increase, cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes)
2254 Increase, cell proliferation (hepatocytes) leads to Increase, hepatocellular adenomas and carcinomas
1239 Increase, cell proliferation (hepatocytes) leads to Increase, Clonal Expansion of Altered Hepatic Foci
714 Binding, Tubulin leads to Disruption, Microtubule dynamics
724 Binding, Tubulin leads to Altered, Chromosome number
715 Disruption, Microtubule dynamics leads to Disorganization, Meiotic Spindle
737 Disorganization, Meiotic Spindle leads to Altered, Meiotic chromosome dynamics
723 Altered, Chromosome number leads to Increase, Aneuploid offspring
716 Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme leads to Increased, Induction of pyruvate dehydrogenase (PDH)
762 Increased, Induction of pyruvate dehydrogenase (PDH) leads to Increase, Oxidative metabolism
726 Increase, Necrosis (terminal bronchiolar cells) leads to Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)
727 Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) leads to Increase, Hyperplasia (terminal bronchiolar cells)
728 Increase, Hyperplasia (terminal bronchiolar cells) leads to Increase, Adenomas/carcinomas (bronchioloalveolar)
768 Decreased, Uptake of inorganic iodide leads to Decrease, Serum thyroid hormone (T4/T3)
2421 Decreased, Uptake of inorganic iodide leads to TH synthesis, Decreased
742 Increase, Hypertrophy and proliferation (follicular cell) leads to Increase, Hyperplasia (follicular cells)
743 Increase, Hyperplasia (follicular cells) leads to Increase, Adenomas/carcinomas (follicular cell)
729 Decreased, Androgen receptor activity leads to Decreased, Testosterone binding to androgen receptor (hypothalamus)
730 Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increase, Hyperplasia (Leydig cells)
744 Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increased, Luteinizing hormone (LH)
731 Increase, Hyperplasia (Leydig cells) leads to Increase, Leydig cell tumors
770 Increase, Dopaminergic activity leads to Increase, Endometrial adenocarcinomas
732 Increase, Dopaminergic activity leads to Decreased, Prolactin
733 Decreased, Prolactin leads to Increased, Estrogen receptor (ER) activity
2737 Increased, Estrogen receptor (ER) activity leads to Increase, Vitellogenin mRNA
734 Increased, Estrogen receptor (ER) activity leads to Decreased, Progesterone from corpus luteum
772 Decreased, Progesterone from corpus luteum leads to Increase, Hyperplasia (glandular epithelial cells of endometrium)
2383 Altered, Meiotic chromosome dynamics leads to Increase, Oocyte apoptosis
2384 Altered, Meiotic chromosome dynamics leads to Decreased spermatogenesis
2391 Altered, Meiotic chromosome dynamics leads to Ionizing Energy
738 Altered, Meiotic chromosome dynamics leads to Altered, Chromosome number
2554 Altered, Meiotic chromosome dynamics leads to Increase, Pollen abnormal
741 Increase, Thyroid-stimulating hormone (TSH) leads to Increase, Hypertrophy and proliferation (follicular cell)
745 Increased, Luteinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells)
2886 Hippocampal gene expression, Altered leads to Hippocampal Physiology, Altered
747 Hippocampal gene expression, Altered leads to Hippocampal anatomy, Altered
749 Hippocampal anatomy, Altered leads to Hippocampal Physiology, Altered
2864 Hippocampal Physiology, Altered leads to Impairment, Learning and memory
2484 Hippocampal Physiology, Altered leads to Loss, Cochlear function
748 Hippocampal Physiology, Altered leads to Cognitive Function, Decreased
2462 Increased, Kidney Failure leads to Increase, Mortality
2466 Increased, Kidney Failure leads to Increased Mortality
752 Activation, Glutamate-gated chloride channel leads to Increased, Chloride conductance
1052 Increased, Chloride conductance leads to Increased, Neuronal synaptic inhibition
758 Increased, Chloride conductance leads to hyperpolarisation, neuron
1051 Activation, ionotropic GABA Receptor chloride channel leads to Increased, Chloride conductance
1566 hyperpolarisation, neuron leads to Analgesia
1572 hyperpolarisation, neuron leads to Anti-depressant Activity
755 hyperpolarisation, neuron leads to N/A, Ataxia, paralysis, or hyperactivity
757 N/A, Ataxia, paralysis, or hyperactivity leads to Increased Mortality
775 Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme leads to Increased, Plasma tyrosine
761 Increase, Hyperplasia (renal tubular cells) leads to Increase, Adenomas/carcinomas (renal tubular)
887 Increase, Cytotoxicity leads to Increase, Tissue Degeneration, Necrosis & Atrophy
766 Increase, Cytotoxicity leads to Increase, hepatocellular adenomas and carcinomas
763 Increase, Oxidative metabolism leads to Peptide Oxidation
767 Increase, Cytotoxicity (club cells) leads to Increase, Necrosis (terminal bronchiolar cells)
769 Decrease, Serum thyroid hormone (T4/T3) leads to Increase, Thyroid-stimulating hormone (TSH)
771 Increase, Hyperplasia (glandular epithelial cells of endometrium) leads to Increase, Endometrial adenocarcinomas
2972 Increase, Hyperplasia (glandular epithelial cells of endometrium) leads to Genomic instability
774 Increase, Preneoplastic foci (hepatocytes) leads to Increase, hepatocellular adenomas and carcinomas
776 Increased, Plasma tyrosine leads to Increase, Cytotoxicity (corneal cells)
777 Increase, Cytotoxicity (corneal cells) leads to Increase, Inflammation (corneal cells)
778 Increase, Inflammation (corneal cells) leads to Increase, Regenerative cell proliferation (corneal cells)
779 Increase, Regenerative cell proliferation (corneal cells) leads to Increase, Papillomas/carcinomas (squamous cells)
780 Increase, Cytotoxicity (epithelial cells) leads to Increase, Inflammation
2659 Increase, Cytotoxicity (epithelial cells) leads to Increased, Reactive oxygen species
2664 Increase, Cytotoxicity (epithelial cells) leads to Secondary genotoxicity
782 Increase, Regenerative cell proliferation (forestomach epithelial cells) leads to Increase, Hyperplasia (forestomach epithelial cells)
783 Increase, Hyperplasia (forestomach epithelial cells) leads to Increase, Papillomas/carcinomas (squamous cells)
784 Increase, Cytotoxicity (tubular epithelial cells) leads to Increase, Regenerative cell proliferation (tubular epithelial cells)
786 Increase, Hyperplasia (tubular epithelial cells) leads to Increase, Adenomas/carcinomas (renal tubular)
787 Activation, Androgen receptor leads to Increase, cell proliferation (hepatocytes)
2908 Activation, Androgen receptor leads to Altered, Transcription of genes by AR
2913 Activation, Androgen receptor leads to Decreased, Apoptosis (Epithelial Cells)
2915 Activation, Androgen receptor leads to Inflammatory events
788 Increase, Cytotoxicity (hepatocytes) leads to Increase, Regenerative cell proliferation (hepatocytes)
789 Increase, Regenerative cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes)
791 Decrease, Incorporation of active iodide into iodotyrosines leads to Decrease, Serum thyroid hormone (T4/T3)
792 Inhibition, 5α-reductase activity leads to Decrease, Bioactivation of testosterone
794 Increased, Leutinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells)
793 Decrease, Bioactivation of testosterone leads to Increased, Leutinizing hormone (LH)
795 Increase, Urinary bladder calculi leads to Increase, Cytotoxicity (urothelial cells)
796 Increase, Cytotoxicity (urothelial cells) leads to Increase, Regenerative cell proliferation (urothelial cells)
797 Increase, Regenerative cell proliferation (urothelial cells) leads to Increase, Hyperplasia (urothelial)
798 Increase, Hyperplasia (urothelial) leads to Increase, Adenomas/carcinomas (urothelial)
2085 Increase, Hyperplasia (urothelial) leads to carcinogenicity
799 Inhibition, Prolyl hydroxylases leads to Increased, HIF-1 heterodimer
800 Increased, HIF-1 heterodimer leads to Decreased, Aromatase (Cyp19a1) mRNA
801 Decreased, Aromatase (Cyp19a1) mRNA leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
802 modulation, Unknown leads to Increased, HIF-1 alpha transcription
803 Increased, HIF-1 alpha transcription leads to Increased, HIF-1 heterodimer
804 Inhibition, HMG-CoA reductase leads to Decreased, mevalonate
805 Decreased, mevalonate leads to Decreased, cholesterol
2072 Decreased, cholesterol leads to Decreased, 11KT
806 Decreased, cholesterol leads to Decreased, Testosterone
807 Decreased, Testosterone leads to malformed, Male reproductive tract
808 malformed, Male reproductive tract leads to Decrease, Fertility
813 Increased, Serum creatinine leads to Occurrence, Cytoplasmic vacuolization (Renal tubule)
814 Increased, Serum creatinine leads to Occurrence, Cystic dilatation (renal tubule)
816 Increased, Serum creatinine leads to Occurrence, Cytoplasmic vacuolization (podocyte)
2648 Occurrence, Kidney toxicity leads to Increased, Kidney Failure
817 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Glomerular filtration
818 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Renal plasma flow
819 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Sodium reabsorption
820 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Renal ability to dilute urine
829 Decreased, Glomerular filtration leads to Occurrence, Kidney toxicity
830 Decreased, Renal plasma flow leads to Occurrence, Kidney toxicity
831 Decreased, Sodium reabsorption leads to Occurrence, Kidney toxicity
821 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Glomerular filtration
822 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Renal plasma flow
823 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Sodium reabsorption
824 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Renal ability to dilute urine
825 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Glomerular filtration
826 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Renal plasma flow
827 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Sodium reabsorption
828 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Renal ability to dilute urine
832 Decreased, Renal ability to dilute urine leads to Occurrence, Kidney toxicity
834 Activation, Keratinocytes leads to Activation, Dendritic Cells
836 Inhibition, Phospholipase A leads to Damage, Lipid bilayer
837 Inhibition, Phospholipase A leads to Disturbance, Lysosomal function
838 Inhibition, Phospholipase A leads to Injury, Mitochondria
839 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
840 Damage, Lipid bilayer leads to Occurrence, Ballooning degeneration (hepatocyte)
841 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
842 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
843 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
844 Disturbance, Lysosomal function leads to Occurrence, Ballooning degeneration (hepatocyte)
845 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
846 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
1678 Disturbance, Lysosomal function leads to Disruption, Lysosome
847 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
848 Injury, Mitochondria leads to Occurrence, Ballooning degeneration (hepatocyte)
849 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
850 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
851 Occurrence, Cytoplasmic vacuolization (hepatocyte) leads to Induction, Microvesicular fat
852 Occurrence, Cytoplasmic vacuolization (hepatocyte) leads to Formation, Mallory body
853 Occurrence, Ballooning degeneration (hepatocyte) leads to Induction, Microvesicular fat
854 Occurrence, Ballooning degeneration (hepatocyte) leads to Formation, Mallory body
855 Occurrence, Cytoplasmic vacuolization (Bile duct cell) leads to Induction, Microvesicular fat
856 Occurrence, Cytoplasmic vacuolization (Bile duct cell) leads to Formation, Mallory body
857 Occurrence, Cytoplasmic vacuolization (kupffer cell) leads to Induction, Microvesicular fat
858 Occurrence, Cytoplasmic vacuolization (kupffer cell) leads to Formation, Mallory body
859 Induction, Microvesicular fat leads to Formation, Liver fibrosis
860 Formation, Mallory body leads to Formation, Liver fibrosis
864 Oxidation, Uroporphyrinogen leads to Accumulation, Highly carboxylated porphyrins
865 Oxidation, Uroporphyrinogen leads to Inhibition, UROD
1070 Inhibition, UROD leads to Accumulation, Highly carboxylated porphyrins
867 Inhibition, UROD leads to Oxidation, Uroporphyrinogen
866 Accumulation, Highly carboxylated porphyrins leads to Uroporphyria
2893 Induction, CYP1A2/CYP1A5 leads to Increase, ROS production
2907 Induction, CYP1A2/CYP1A5 leads to Increase, Oxidative Stress
868 Induction, CYP1A2/CYP1A5 leads to Oxidation, Uroporphyrinogen
871 GABAergic interneurons, Decreased leads to Synaptogenesis, Decreased
995 Changes/Inhibition, Cellular Homeostasis and Apoptosis leads to N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
2911 Alterations, Cellular proliferation / hyperplasia leads to prostatic intraepithelial neoplasia
997 Alterations, Cellular proliferation / hyperplasia leads to Formation, Hepatocellular and Bile duct tumors
877 Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain leads to Decreased, PPARalpha transactivation of gene expression
878 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
879 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
880 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Ketogenesis (production of ketone bodies)
1748 Decreased, PPARalpha transactivation of gene expression leads to Fatty Acid Beta Oxidation, Decreased
881 Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
882 Decreased, Mitochondrial Fatty Acid Beta Oxidation leads to Decreased, Ketogenesis (production of ketone bodies)
2264 Decreased, Mitochondrial Fatty Acid Beta Oxidation leads to Accumulation, Triglyceride
2040 Decreased, Mitochondrial Fatty Acid Beta Oxidation leads to Increased, Liver Steatosis
883 Decreased, Ketogenesis (production of ketone bodies) leads to Not Increased, Circulating Ketone Bodies
884 Not Increased, Circulating Ketone Bodies leads to Increased, Catabolism of Muscle Protein
885 Increased, Catabolism of Muscle Protein leads to Decreased, Body Weight
886 Decrease, Intracellular pH leads to Increase, Cytotoxicity
888 Increase, Tissue Degeneration, Necrosis & Atrophy leads to Increase, Respiratory or Squamous Metaplasia
889 Increase, Respiratory or Squamous Metaplasia leads to Increase, Cell Proliferation
2819 Increase, Cell Proliferation leads to Cataracts
2419 Increase, Cell Proliferation leads to Increased, mesotheliomas
890 Increase, Cell Proliferation leads to Increased, Induced Mutations in Critical Genes
893 Increase, Cell Proliferation leads to Increase, Mutations in Critical Genes
895 Increase, Cell Proliferation leads to Increase, Site of Contact Nasal Tumors
1967 Increase, Cell Proliferation leads to Lung cancer
1980 Increase, Cell Proliferation leads to Increase, lung cancer
919 Binding of agonist, Ionotropic glutamate receptors leads to Overactivation, NMDARs
894 Increase, Mutations in Critical Genes leads to Increase, Site of Contact Nasal Tumors
1131 Inhibition, organic anion transporter 1 (OAT1) leads to Increased, blood uric acid concentration
1809 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to Decrease, OXPHOS
1940 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to Decrease in mitochondrial oxidative phosphorylation
934 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to N/A, Mitochondrial dysfunction 1
933 Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) leads to Inhibition, NADH-ubiquinone oxidoreductase (complex I)
905 Impaired, Proteostasis leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
1943 Impaired, Proteostasis leads to Cell injury/death
907 Degeneration of dopaminergic neurons of the nigrostriatal pathway leads to Neuroinflammation
910 Degeneration of dopaminergic neurons of the nigrostriatal pathway leads to Parkinsonian motor deficits
911 Disruption, Lysosome leads to Increase, ROS production
1679 Disruption, Lysosome leads to Increase, Cytotoxicity (renal tubular cell)
921 Disruption, Lysosome leads to Peptide Oxidation
993 Disruption, Lysosome leads to N/A, Mitochondrial dysfunction 1
916 Infiltration, Inflammatory cells leads to Inflammation, Liver
926 Infiltration, Inflammatory cytokines leads to Inflammation, Liver
936 Activation, Epidermal Growth Factor Receptor leads to Decreased ciliated cell apoptosis
939 Activation, Epidermal Growth Factor Receptor leads to Increased goblet cell proliferation
942 Activation, Epidermal Growth Factor Receptor leads to Occurrence, Transdifferentiation of ciliated epithelial cells
946 Activation, Epidermal Growth Factor Receptor leads to Activation, Sp1
2470 Decreased ciliated cell apoptosis leads to Goblet cell metaplasia
961 Decreased ciliated cell apoptosis leads to Occurrence, Transdifferentiation of ciliated epithelial cells
943 Occurrence, Transdifferentiation of ciliated epithelial cells leads to Goblet cell metaplasia
1313 Goblet cell metaplasia leads to Increase, Mucin production
2471 Goblet cell metaplasia leads to Chronic, Mucus hypersecretion
990 Goblet cell metaplasia leads to Hypersecretion, Mucus
1312 Goblet cell hyperplasia leads to Increase, Mucin production
2472 Goblet cell hyperplasia leads to Chronic, Mucus hypersecretion
989 Goblet cell hyperplasia leads to Hypersecretion, Mucus
944 Increased goblet cell proliferation leads to Goblet cell hyperplasia
987 Activation, Sp1 leads to Increase, Mucin production
2459 Oxidation, Glutathione leads to Increased, Reactive oxygen species
954 Oxidation, Glutathione leads to S-Glutathionylation, eNOS
955 S-Glutathionylation, eNOS leads to Uncoupling, eNOS
956 Uncoupling, eNOS leads to Depletion, Nitric Oxide
3014 Uncoupling, eNOS leads to Increase, Vascular disrupting effects
3023 Uncoupling, eNOS leads to increased，Vascular endothelial dysfunction
958 Depletion, Nitric Oxide leads to Impaired, Vasodilation
953 Decrease, Tetrahydrobiopterin leads to Uncoupling, eNOS
952 Decrease, GTPCH-1 leads to Decrease, Tetrahydrobiopterin
982 Impaired, Vasodilation leads to Increase, Vascular Resistance
2857 Activation, EGFR leads to Increase, goblet cell number
2469 Activation, EGFR leads to Goblet cell metaplasia
962 Activation, EGFR leads to Decreased ciliated cell apoptosis
964 Activation, EGFR leads to Activation, Sp1
965 Activation, EGFR leads to Occurrence, Transdifferentiation of ciliated epithelial cells
970 Activation, EGFR leads to Increased goblet cell proliferation
986 Activation, EGFR leads to Increase, Mucin production
1350 dimerization, AHR/ARNT leads to Increase, COX-2 expression
2682 dimerization, AHR/ARNT leads to Decrease, sox9 expression
2683 dimerization, AHR/ARNT leads to Increase, slincR expression
1996 dimerization, AHR/ARNT leads to Increase, DNMT expression
973 dimerization, AHR/ARNT leads to reduced dimerization, ARNT/HIF1-alpha
974 reduced dimerization, ARNT/HIF1-alpha leads to reduced production, VEGF
2407 reduced production, VEGF leads to abnormal, placental labyrinth vasculature morphology
975 reduced production, VEGF leads to Impairment, Endothelial network
983 Increase, Vascular Resistance leads to Hypertension
2245 Binding, Transthyretin in serum leads to Displacement, Serum thyroxine (T4) from transthyretin
2248 Binding, Transthyretin in serum leads to Displacement, Serum thyroxine (T4) from carrier protein
2269 Binding, Transthyretin in serum leads to Increased, Clearance of thyroxine from serum
2271 Binding, Transthyretin in serum leads to Increased, Free serum thyroxine (T4)
2246 Displacement, Serum thyroxine (T4) from transthyretin leads to Increased, Free serum thyroxine (T4)
2247 Increased, Free serum thyroxine (T4) leads to Increased, Hepatic thyroid hormone uptake/transport
2268 Increased, Free serum thyroxine (T4) leads to Increased, Uptake of thyroxine into tissue
2272 Increased, Free serum thyroxine (T4) leads to Increased, Clearance of thyroxine from serum
2270 Increased, Clearance of thyroxine from serum leads to T4 in serum, Decreased
1315 Increase, Mucin production leads to Chronic, Mucus hypersecretion
2859 Increase, Mucin production leads to Decreased lung function
991 Increase, Mucin production leads to Hypersecretion, Mucus
988 Decrease, AKT/eNOS activity leads to Depletion, Nitric Oxide
1062 Formation, The binding of FK506 with FKBP12 leads to Inhibition, Calcineurin Activity
1016 Activation, Suppression of NFAT activation and hindrance of nuclear localization leads to Interference, nuclear localization of NFAT
1017 Interference, nuclear localization of NFAT leads to Reduction, NFAT/AP-1 complex formation
1508 Inhibition, Calcineurin Activity leads to Interference, nuclear localization of NFAT
1254 Inhibition, Calcineurin Activity leads to Suppression, IL-2 and IL-4 production
1015 Inhibition, Calcineurin Activity leads to Activation, Suppression of NFAT activation and hindrance of nuclear localization
1509 Reduction, NFAT/AP-1 complex formation leads to Suppression, IL-2 and IL-4 production
1256 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of production of cytotoxic T-cells
1257 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of T-cell dependent antibody production
1018 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression in mixed lymphocyte reaction (MLR)
1019 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of T-cell dependent antibody response (TDAR)
1020 Reduction, NFAT/AP-1 complex formation leads to Impairment, T-cell dependent antibody response
1021 Reduction, NFAT/AP-1 complex formation leads to Relief, Relief of atopic dermatitis
1022 Reduction, NFAT/AP-1 complex formation leads to Impairment of TDAR
1823 Suppression, Suppression of T-cell dependent antibody response (TDAR) leads to Impairment of TDAR
1346 Decrease, Circulating ETH leads to Decrease, Circulating CCAP
1000 Decrease, Circulating ETH leads to Increase, Incomplete ecdysis
1008 Decrease, Circulating ETH leads to Decrease, Abdominal muscle contraction
1001 Decreased, synthesis and secretion of molting fluid proteases leads to Increase, Incomplete ecdysis
1190 Increase, Incomplete ecdysis leads to Increased Mortality
2750 Increase, Incomplete ecdysis leads to Increase, delay in oviposition
2751 Increase, Incomplete ecdysis leads to Decrease, hatching of egg
2759 Increase, Incomplete ecdysis leads to Increase, developmental abnormalities
1002 Increase, Incomplete ecdysis leads to Increase, Mortality
1010 Decrease, Abdominal muscle contraction leads to Increase, Incomplete ecdysis
1009 Decreased, Synthesis of molting fluid proteases leads to Decrease, Digestion of old cuticle
2171 Decrease, Digestion of old cuticle leads to Increase, Premature molting
1011 Decrease, Digestion of old cuticle leads to Increase, Incomplete ecdysis
1023 Binding of antagonist, PPAR alpha leads to stabilization, PPAR alpha co-repressor
1024 stabilization, PPAR alpha co-repressor leads to Decreased, PPARalpha transactivation of gene expression
1026 Inhibition, Deiodinase 2 leads to Decreased, Triiodothyronine (T3)
1042 Inhibition, Deiodinase 2 leads to Reduced, Posterior swim bladder inflation
1043 Inhibition, Deiodinase 2 leads to Reduced, Anterior swim bladder inflation
1199 Inhibition, Deiodinase 2 leads to Decreased, Triiodothyronine (T3) in tissues
1027 Decreased, Triiodothyronine (T3) leads to Reduced, Posterior swim bladder inflation
1035 Decreased, Triiodothyronine (T3) leads to Reduced, Anterior swim bladder inflation
2373 Decreased, Triiodothyronine (T3) leads to Altered, retinal layer structure
2376 Decreased, Triiodothyronine (T3) leads to Decreased, Eye size
2378 Decreased, Triiodothyronine (T3) leads to Altered, Photoreceptor patterning
1028 Reduced, Posterior swim bladder inflation leads to Reduced, Swimming performance
1031 Reduced, Posterior swim bladder inflation leads to Reduced, Anterior swim bladder inflation
2213 Reduced, Posterior swim bladder inflation leads to Increased Mortality
2081 Reduced, Swimming performance leads to Decrease, Population growth rate
1641 Reduced, Swimming performance leads to Growth, reduction
1642 Reduced, Swimming performance leads to Decreased, survival
2212 Reduced, Swimming performance leads to Increased Mortality
1032 Reduced, Anterior swim bladder inflation leads to Reduced, Hearing
1034 Reduced, Anterior swim bladder inflation leads to Reduced, Swimming performance
2231 Reduced, Hearing leads to Increased Mortality
1037 Inhibition, Deiodinase 1 leads to Decreased, Triiodothyronine (T3)
1044 Inhibition, Deiodinase 1 leads to Reduced, Posterior swim bladder inflation
1045 Inhibition, Deiodinase 1 leads to Reduced, Anterior swim bladder inflation
1198 Inhibition, Deiodinase 1 leads to Decreased, Triiodothyronine (T3) in tissues
1047 Increased, Chloride influx leads to Increased, Inhibitory postsynaptic potential
1048 Increased, Inhibitory postsynaptic potential leads to Inhibition, Motor neuron activity
1054 Increased, Inhibitory postsynaptic potential leads to Induction, Somatic muscle paralysis
1058 Increased, Inhibitory postsynaptic potential leads to Induction, pharyngeal muscle paralysis
1049 Inhibition, Motor neuron activity leads to Induction, Somatic muscle paralysis
1050 Induction, Somatic muscle paralysis leads to Increased Mortality
1055 Induction, Somatic muscle paralysis leads to Inhibition, Feeding
1053 Increased, Neuronal synaptic inhibition leads to Increased, Inhibitory postsynaptic potential
1056 Inhibition, Feeding leads to Increased Mortality
1057 Activation, Glutamate-gated chloride channels leads to Increased, Chloride conductance
1059 Induction, pharyngeal muscle paralysis leads to Inhibition, Feeding
1063 Increased, induction of UDPGT's in liver leads to Increased, T4/T3 catabolism
1064 Increased, T4/T3 catabolism leads to Decreased, serum T4/T3
2423 Increased, T4/T3 catabolism leads to T4 in serum, Decreased
1065 Decreased, serum T4/T3 leads to Increased, Thyroid-stimulating hormone (TSH)
1066 Increased, Thyroid-stimulating hormone (TSH) leads to Increased, Hypertrophy and proliferation (follicular cell)
2424 Increased, Thyroid-stimulating hormone (TSH) leads to Increase, Hypertrophy and proliferation (follicular cell)
2425 Increased, Thyroid-stimulating hormone (TSH) leads to Increase, Thyroid-stimulating hormone (TSH)
2240 Increased, Thyroid-stimulating hormone (TSH) leads to Increased, Thyroxine (T4) in serum
1067 Increased, Hypertrophy and proliferation (follicular cell) leads to Increased, Hyperplasia (follicular cells)
2427 Increased, Hypertrophy and proliferation (follicular cell) leads to Increase, Hyperplasia (follicular cells)
1068 Increased, Hyperplasia (follicular cells) leads to Increased Apoptosis, Adenomas/carcinomas (follicular cell)
2426 Increased, Hyperplasia (follicular cells) leads to Increase, Adenomas/carcinomas (follicular cell)
1071 Activation of specific nuclear receptors, PPAR-gamma activation leads to Increased, adipogenesis
1072 Activation of specific nuclear receptors, PPAR-gamma activation leads to Increased, secretion of local growth factors
1609 Activation of specific nuclear receptors, PPAR-gamma activation leads to increased adipogenesis
1073 Increased, adipogenesis leads to Increased, secretion of local growth factors
1074 Increased, secretion of local growth factors leads to Increased, proliferation of mesenchymal cells
1075 Increased, secretion of local growth factors leads to Increased, IGF-1 (mouse)
1624 Increased, secretion of local growth factors leads to Differentiation of fibroblasts
1625 Increased, secretion of local growth factors leads to EMT
1129 Increased, secretion of local growth factors leads to Increased, Cell Proliferation (mesothelium)
1076 Increased, proliferation of mesenchymal cells leads to Increased, Firbrosarcoma
1077 Increased, proliferation of mesenchymal cells leads to Increased, liposarcoma
1078 Increased, proliferation of mesenchymal cells leads to Increased, hemagiosarcoma
1079 Activation, beta-2 adrenergic receptor leads to Increased activity, beta-2 adrenergic receptor
1080 Increased activity, beta-2 adrenergic receptor leads to relaxation, smooth muscle
1081 relaxation, smooth muscle leads to Proliferation/Clonal Expansion, smooth muscle
1082 Proliferation/Clonal Expansion, smooth muscle leads to Hypertrophy/hyperplasia, smooth muscle
1083 Hypertrophy/hyperplasia, smooth muscle leads to Promotion, mesovarian leiomyomas
1084 Decreased, Ovarian E2 leads to Increased, secretion of GnRH from hypothalamus
1085 Decreased, Ovarian E2 leads to Decrease, E2 blood concentrations at hypothalamus
2580 Suppression, Estrogen receptor (ER) activity leads to Increased, secretion of GnRH from hypothalamus
1086 Suppression, Estrogen receptor (ER) activity leads to Decrease, E2 blood concentrations at hypothalamus
1088 Increased, secretion of GnRH from hypothalamus leads to Increased, secrection of FSH from anterior pituitary
1089 Increased, secretion of GnRH from hypothalamus leads to Increased, secretion of LH from anterior pituitary
1090 Increased, secrection of FSH from anterior pituitary leads to Hyperplasia, ovarian stromal cells
1091 Increased, secrection of FSH from anterior pituitary leads to Hyperplasia, ovarian epithelium
2581 Increased, secretion of LH from anterior pituitary leads to Increased, Steroidogenic acute regulatory protein (StAR)
1092 Increased, secretion of LH from anterior pituitary leads to Hyperplasia, ovarian stromal cells
1094 Hyperplasia, ovarian stromal cells leads to Promotion, ovarian granular cell tumors
1093 Hyperplasia, ovarian epithelium leads to Promotion, ovarian adenomas
2829 Promotion, ovarian adenomas leads to Promotion, Ovarian Cancer
2830 Promotion, ovarian granular cell tumors leads to Promotion, Ovarian Cancer
1087 Decrease, E2 blood concentrations at hypothalamus leads to Increased, secretion of GnRH from hypothalamus
1095 Increased, PPAR-alpha activation leads to Decreased, bile flow
1096 Increased, PPAR-alpha activation leads to Increased, cholestasis
1097 Increased, PPAR-alpha activation leads to Alteration, lipid metabolism
1101 Decreased, bile flow leads to Increased, cholestasis
1100 Increased, cholestasis leads to prolonged, elevation of serun CCK
1098 prolonged, elevation of serun CCK leads to Increased, Cellular proliferation / hyperplasia of acinar cells
1099 Increased, Cellular proliferation / hyperplasia of acinar cells leads to Increased, Pancreatic acinar tumors
1102 prepubertal increase, Estrogen receptor (ER) activity leads to Activation, estrogen receptor alpha
1103 Activation, estrogen receptor alpha leads to Promotion, SIX-1 postive basal-type progenitor cells
2665 Activation, estrogen receptor alpha leads to Increased, Kisspeptin signalling
2666 Activation, estrogen receptor alpha leads to Decreased, Gonadotropins
2969 Activation, estrogen receptor alpha leads to Epigenetic modification process
2730 Activation, estrogen receptor alpha leads to Impaired, Reproduction
1104 Promotion, SIX-1 postive basal-type progenitor cells leads to Proliferation/Clonal Expansion, aberrant basal cells
1105 Proliferation/Clonal Expansion, aberrant basal cells leads to squamous metaplasia, aberrant basal cells
1106 squamous metaplasia, aberrant basal cells leads to Increased, Hyperplasia (glandular epithelial cells of endometrium)
1107 Increased, Hyperplasia (glandular epithelial cells of endometrium) leads to Increased, adenosquamous carcinomas of endometrium
1108 Decreased, GnRH pulsatility/release in hypothalamus leads to Decreased, LH Surge from anterior pituitary
1109 Decreased, LH Surge from anterior pituitary leads to interruption, Ovulation
1110 Decreased, LH Surge from anterior pituitary leads to prolonged, estrus
1118 interruption, Ovulation leads to Increased, circulating estrogen levels
1111 prolonged, estrus leads to Increased, circulating estrogen levels
1112 prolonged, estrus leads to Increased, prolactin exposure
2584 Increased, circulating estrogen levels leads to Hyperplasia, ovarian stromal cells
2585 Increased, circulating estrogen levels leads to Hyperplasia, ovarian epithelium
1113 Increased, circulating estrogen levels leads to Hyperplasia, Mammary gland
1119 Increased, circulating estrogen levels leads to Increased, lactotroph hyperplasia and hypertrophy
1114 Increased, prolactin exposure leads to Hyperplasia, Mammary gland
1115 Hyperplasia, Mammary gland leads to Increased, latency period
1116 Hyperplasia, Mammary gland leads to Increased, Adenomas/carcinomas (mammary)
1117 Increased, latency period leads to Increased, Adenomas/carcinomas (mammary)
1120 Increased, lactotroph hyperplasia and hypertrophy leads to Increased, adenomas (pituitary)
1121 Decreased, Dopaminergic activity leads to Increased, prolactin secretion
1122 Increased, prolactin secretion leads to Increased, hyperplasia (mammary gland)
1123 Increased, hyperplasia (mammary gland) leads to Increased, latency period
1124 Increased, hyperplasia (mammary gland) leads to Increased, Adenomas/carcinomas (mammary)
1125 persistent, cytotoxicity (pleura or peritoneum) leads to Increased, inflammation
1126 persistent, cytotoxicity (pleura or peritoneum) leads to Increased, Oxidative Stress
1127 Increased, inflammation leads to Increased, secretion of local growth factors
1300 Increased, Oxidative Stress leads to Increase, DNA Damage
2618 Increased, Oxidative Stress leads to Increase, Apoptosis
2385 Increased, Oxidative Stress leads to Increase, Oocyte apoptosis
1128 Increased, Oxidative Stress leads to Increased, secretion of local growth factors
2933 Increased, Oxidative Stress leads to Impaired insulin signaling
2936 Increased, Oxidative Stress leads to Mitochondrial dysfunction
1160 Increased, Oxidative Stress leads to Occurrence, renal proximal tubular necrosis
1130 Increased, Cell Proliferation (mesothelium) leads to Increased, mesotheliomas
1142 Decreased, Thyroxine (T4) in tissues leads to Altered, Amphibian metamorphosis
1163 Decreased, Thyroxine (T4) in tissues leads to Decreased, Triiodothyronine (T3) in tissues
1132 Increased, blood uric acid concentration leads to Occurrence, tophi (urate) deposition
1158 Increased, blood uric acid concentration leads to Increased, Oxidative Stress
2647 Occurrence, renal proximal tubular necrosis leads to Occurrence, Kidney toxicity
1134 Occurrence, renal proximal tubular necrosis leads to Increased, blood potassium concentration
1156 Occurrence, renal proximal tubular necrosis leads to Increased, blood uric acid concentration
1135 Increased, blood potassium concentration leads to Occurrence, cardiac arrthymia
1140 Increased, blood potassium concentration leads to Occurrence, cardiac arrhythmia
1136 Occurrence, cardiac arrthymia leads to Increased Mortality
1133 Occurrence, tophi (urate) deposition leads to Occurrence, renal proximal tubular necrosis
1137 Inhibition, Cyclooxygenase 1 activity leads to Decreased, Prostaglandin F2alpha concentration, plasma
1138 Decreased, Prostaglandin F2alpha concentration, plasma leads to Occurrence, renal ischemia
1139 Occurrence, renal ischemia leads to Occurrence, renal proximal tubular necrosis
1159 Occurrence, renal ischemia leads to Increased, Oxidative Stress
2854 Occurrence, cardiac arrhythmia leads to Increased，Cardiac dysfunction
1141 Occurrence, cardiac arrhythmia leads to Increased Mortality
1145 Weakened, Colony leads to Death/Failure, Colony
1151 Abnormal, Role change within caste leads to Weakened, Colony
1155 Increased, Deformed Wing Virus levels leads to Weakened, Colony
1157 Increased, Energetic demands and therefore metabolic stress leads to Abnormal, Foraging activity and behavior
1161 Unknown, MIE leads to Increased, Reactive oxygen species
2035 Unknown, MIE leads to Unknown,
2036 Unknown, MIE leads to N/A, Unknown
2320 Increased, Reactive oxygen species leads to Increased activation, Nuclear factor kappa B (NF-kB)
2324 Increased, Reactive oxygen species leads to Increased extracellular matrix deposition
2328 Increased, Reactive oxygen species leads to Increased Sodium-sensitive hypertension
2594 Increased, Reactive oxygen species leads to Accumulation, Collagen
2660 Increased, Reactive oxygen species leads to Secondary genotoxicity
1162 Increased, Reactive oxygen species leads to Increased, Oxidative Stress
2966 Increased, Reactive oxygen species leads to Apoptosis
2460 Increased, Reactive oxygen species leads to Increased, LPO
1696 Increased, Reactive oxygen species leads to increased, oncotic necrosis
1965 Increased, Reactive oxygen species leads to Increased, DNA damage and mutation
2009 Increased, Reactive oxygen species leads to Oxidative Stress
2033 Increased, Reactive oxygen species leads to β-catenin activation
2549 Increased, Reactive oxygen species leads to D1 protein deactivation
2550 Increased, Reactive oxygen species leads to Decrease, MMP
1164 Decreased, Triiodothyronine (T3) in tissues leads to Altered, Amphibian metamorphosis
2238 Decreased, Triiodothyronine (T3) in tissues leads to Increased, Thyroid-stimulating hormone (TSH)
2239 Decreased, Triiodothyronine (T3) in tissues leads to Altered, TH-dependent gene expression
1168 Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur leads to Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
1169 Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) leads to Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis
1165 Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo leads to Hemostasis, Depletion from blood of fully functional carboxylated clotting factors
1170 Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis leads to Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction
1166 Hemostasis, Depletion from blood of fully functional carboxylated clotting factors leads to Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur
1167 Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle leads to Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo
1171 Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction leads to Impaired recruitment , Population trajectory
1175 Increased, water retention in foot leads to Increased, foot detachment
1223 Increased, water retention in foot leads to Increased, valve movement
1182 Delayed, Sexual maturity leads to Decreased, Reproductive Success
2635 Decreased, Reproductive Success leads to Decrease, Population growth rate
1320 Increased, valve movement leads to induced spawning
1334 Increased, valve movement leads to Induced parturition
1173 Increased, valve movement leads to Depletion, energy reserves
1174 Increased, valve movement leads to Increased, water retention in foot
1216 Increased, valve movement leads to Increased, water pumping
1227 Increased, valve movement leads to Increase, predation
1181 Depletion, energy reserves leads to Delayed, Sexual maturity
1185 Depletion, energy reserves leads to Increase, predation
1179 premature, spawning 1 leads to Decreased, Reproductive Success
1188 Decreased, gametogenesis leads to Decreased, Reproductive Success
1211 premature, Spawning leads to Increased, Population
1222 premature, Spawning leads to Decreased, Reproductive Success
1193 increased or inappropriate, mantel display leads to Decreased, Reproductive Success
1219 increased or inappropriate, mantel display leads to Depletion, energy reserves
1220 increased or inappropriate, mantel display leads to induced, parturition
1194 Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p leads to Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei
1195 Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei leads to Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp
1196 Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp leads to Osteoporosis and vascular calcification, Bone deterioration
2476 Inhibition, Iodotyrosine deiodinase (IYD) leads to T4 in serum, Decreased
1197 Inhibition, Iodotyrosine deiodinase (IYD) leads to Thyroidal Iodide, Decreased
1200 Inhibition, Deiodinase 3 leads to Increased, Triiodothyronine (T3) in tissues
1201 Increased, Triiodothyronine (T3) in tissues leads to Altered, Amphibian metamorphosis
2243 Increased, Triiodothyronine (T3) in tissues leads to Altered, TH-dependent gene expression
1202 Inhibition, Pendrin leads to TH synthesis, Decreased
1203 Inhibition, Dual oxidase leads to TH synthesis, Decreased
1204 Activation, Hepatic nuclear receptor(s) leads to Increased, Hepatic thyroid hormone uptake/transport
1205 Activation, Hepatic nuclear receptor(s) leads to Induction, Upregulation of glucuronyltransferase activity
2479 Increased, Hepatic thyroid hormone uptake/transport leads to Increased, Clearance of thyroxine from serum
1206 Increased, Hepatic thyroid hormone uptake/transport leads to Increase, Biliary excretion TH glucuronide
2237 Increased, Hepatic thyroid hormone uptake/transport leads to T4 in serum, Decreased
1214 Increased, mantel display leads to Increased, Reproductive Success
1328 Increased, oocyte maturation leads to induced spawning
1213 Increased, oocyte maturation leads to Increased, Reproductive Success
1329 Increased, cilia movement leads to induced spawning
1210 Increased, cilia movement leads to premature, Spawning
1215 Increased, Reproductive Success leads to Increased, Population
1224 Increased, water pumping leads to Increased, water retention in foot
1225 Increased, water pumping leads to premature, Spawning
1226 Increased, water pumping leads to induced, parturition
1221 induced, parturition leads to Decreased, Reproductive Success
1230 Increase, Phenotypic enzyme activity leads to Increase, cell proliferation (hepatocytes)
1231 Increase, Phenotypic enzyme activity leads to Increase, Clonal Expansion of Altered Hepatic Foci
1232 Increase, Clonal Expansion of Altered Hepatic Foci leads to Increase, hepatocellular adenomas and carcinomas
2309 Increased activation, Nuclear factor kappa B (NF-kB) leads to Increased proinflammatory mediators
2612 Increased activation, Nuclear factor kappa B (NF-kB) leads to Antagonism, Estrogen receptor
2431 Increased activation, Nuclear factor kappa B (NF-kB) leads to Release, Cytokine
2432 Increased activation, Nuclear factor kappa B (NF-kB) leads to Increased pro-inflammatory mediators
1238 Increased activation, Nuclear factor kappa B (NF-kB) leads to Increase, Phenotypic enzyme activity
1241 Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids leads to Peptide Oxidation
1360 Activation, NADPH Oxidase leads to ROS formation
1235 Activation, NADPH Oxidase leads to Peptide Oxidation
1234 Increase, Genes involved in fatty acid oxidation leads to Peptide Oxidation
1240 Increase, Genes involved in fatty acid oxidation leads to Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
1243 Decreased, sodium conductance 2 leads to Decreased, Ionotropic GABA receptor chloride channel conductance
1244 Decreased, sodium conductance 2 leads to Decreased, GABA release
1245 Decreased, GABA release leads to Decreased, Chloride conductance
1294 Activation, Estrogen receptor leads to Increased, Non-genomic signaling
1307 Activation, Estrogen receptor leads to Increased, Second Messenger Production
1246 Activation, Estrogen receptor leads to Increased, ER binding to DNA (classical pathway)
1249 Activation, Estrogen receptor leads to Increased, ER binding to T.F. to DNA (non-classical pathway)
1907 Increase, Cell Proliferation (Epithelial Cells) leads to Increase, Mutations
1247 Increase, Cell Proliferation (Epithelial Cells) leads to Increased, Ductal Hyperplasia
2914 Decreased, Apoptosis (Epithelial Cells) leads to Alterations, Cellular proliferation / hyperplasia
1248 Decreased, Apoptosis (Epithelial Cells) leads to Increased, Ductal Hyperplasia
1296 Increased, ER binding to DNA (classical pathway) leads to Altered, Gene Expression
1250 Increased, ER binding to DNA (classical pathway) leads to Increase, Cell Proliferation (Epithelial Cells)
1297 Increased, ER binding to T.F. to DNA (non-classical pathway) leads to Altered, Gene Expression
1251 Increased, ER binding to T.F. to DNA (non-classical pathway) leads to Increase, Cell Proliferation (Epithelial Cells)
1266 Increased, Proliferation (Endothelial cells) leads to Increased, Angiogenesis
2575 Increased, Migration (Endothelial Cells) leads to Increase, angiogenesis
1267 Increased, Migration (Endothelial Cells) leads to Increased, Angiogenesis
1295 Increased, Non-genomic signaling leads to Increased, ER binding to T.F. to DNA (non-classical pathway)
1302 Increased, Non-genomic signaling leads to Altered, Gene Expression
1252 Increased, Ductal Hyperplasia leads to N/A, Breast Cancer
1301 Increase, DNA Damage leads to Altered, Gene Expression
2338 Increase, DNA Damage leads to Increase, Programmed cell death
2595 Increase, DNA Damage leads to Activation of TP53
2622 Increase, DNA Damage leads to Decreased spermatogenesis
2381 Increase, DNA Damage leads to Altered, Meiotic chromosome dynamics
2382 Increase, DNA Damage leads to Increase, Oocyte apoptosis
1897 Increase, DNA Damage leads to Increase, Mutations
1898 Increase, DNA Damage leads to Tissue resident cell activation
1899 Increase, DNA Damage leads to Increase mutations
1468 Increase, DNA Damage leads to Increase, Apoptosis
2790 Increase, DNA Damage leads to Cell cycle, disrupted
2576 Increased, Invasion leads to N/A, Breast Cancer
1253 Binding, Immunophilins leads to Inhibition, Calcineurin Activity
1510 Suppression, IL-2 and IL-4 production leads to Impairment, T-cell dependent antibody response
1255 Suppression, IL-2 and IL-4 production leads to Interference, nuclear localization of NFAT
1258 Suppression, Suppression of production of cytotoxic T-cells leads to Impairment, T-cell dependent antibody response
1260 Suppression, Suppression of production of cytotoxic T-cells leads to Impairment of TDAR
1259 Suppression, Suppression of T-cell dependent antibody production leads to Impairment of TDAR
1261 Activation, Juvenile hormone receptor leads to Induction, Doublesex1 gene
1262 Induction, Doublesex1 gene leads to Induction, Male reproductive tract
1264 Increased, Male offspring leads to Decline, Population
1263 Induction, Male reproductive tract leads to Increased, Male offspring
1269 Altered expression of hepatic CAR-dependent genes leads to Increase, cell proliferation (hepatocytes)
1284 TRPA1 activation, TRPA1 Receptor leads to Non-neuronal production of IL-8/CXCL1, Epithelial irritation
1576 TRPA1 activation, TRPA1 Receptor leads to Generation of novel epitopes , Antigen presentation
1271 TRPA1 activation, TRPA1 Receptor leads to Opening of calcium channel, Calcium influx
1273 Sensory Airway Irritation leads to Cough, Dyspnea, Sneezing, Acute respiratory effect
1280 Opening of calcium channel, Calcium influx leads to SP (Substance P) release, Local increase of SP
1272 Opening of calcium channel, Calcium influx leads to Sensory Airway Irritation
1274 Opening of calcium channel, Calcium influx leads to Excitation, Trigeminal nerve excitation
1575 Excitation, Trigeminal nerve excitation leads to SP (Substance P) release, Local increase of SP
1578 Excitation, Trigeminal nerve excitation leads to Increased CGRP
1582 Excitation, Trigeminal nerve excitation leads to Irritation induced sneezing
1583 Excitation, Trigeminal nerve excitation leads to Increased NKA
1275 Excitation, Trigeminal nerve excitation leads to Cough, Dyspnea, Sneezing, Acute respiratory effect
1276 Excitation, Trigeminal nerve excitation leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1574 SP (Substance P) release, Local increase of SP leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1577 SP (Substance P) release, Local increase of SP leads to Leukocyte infiltration
1772 SP (Substance P) release, Local increase of SP leads to Respiratory irritability
1279 SP (Substance P) release, Local increase of SP leads to Non-neuronal production of TNF, Epithelial irritation
1771 Increased Airway Hyper-responsiveness,Cough, Dyspnea leads to Respiratory irritability
1288 Non-neuronal production of TNF, Epithelial irritation leads to Opening of calcium channel, Calcium influx
1277 Non-neuronal production of TNF, Epithelial irritation leads to Leukocyte infiltration
1290 Leukocyte infiltration leads to Sensitization, Immune system
1278 Leukocyte infiltration leads to Respiratory irritability
1770 Respiratory irritability leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1281 TRPV1 activation, TRPV1 leads to Opening of calcium channel, Calcium influx
1282 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to TRPA1 activation, TRPA1 Receptor
1285 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to Generation of novel epitopes , Antigen presentation
1286 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to Production of nerve growth factor , Epithelial irritation
1283 Production of nerve growth factor , Epithelial irritation leads to SP (Substance P) release, Local increase of SP
1287 Non-neuronal production of IL-8/CXCL1, Epithelial irritation leads to Opening of calcium channel, Calcium influx
1289 Generation of novel epitopes , Antigen presentation leads to Sensitization, Immune system
1291 Oxidation leads to Generation of novel epitopes , Antigen presentation
1292 Oxidation leads to TRPA1 activation, TRPA1 Receptor
1293 Oxidation leads to Production of nerve growth factor , Epithelial irritation
1807 Altered, Gene Expression leads to Altered differentiation
1298 Altered, Gene Expression leads to Altered, Protein Production
1299 Altered, Protein Production leads to Increased, Oxidative Stress
1303 Altered, Protein Production leads to Increased, Proliferation (Endothelial cells)
1304 Altered, Protein Production leads to Decreased, Apoptosis (Epithelial Cells)
1305 Altered, Protein Production leads to Increased, Motility
1306 Increased, Motility leads to Increased, Invasion
1308 Increased, Second Messenger Production leads to Increased, Non-genomic signaling
1310 Altered, Ca2+-calmodulin activated signal transduction leads to Impairment, Learning and memory
1314 Chronic, Mucus hypersecretion leads to Decreased lung function
1330 Binding, topoisomerase II leads to MLL translocation
1634 Binding, topoisomerase II leads to DSB
1331 MLL translocation leads to IFL
1324 induced spawning leads to Decreased, Reproductive Success
1325 induced spawning leads to Increased, Reproductive Success
1322 increased mantel display leads to Induced parturition
1323 Induced parturition leads to Decreased, Reproductive Success
1326 Induced parturition leads to Increased, Reproductive Success
1338 Decompartmentalization leads to Mitochondrial impairment
1340 narcosis leads to Mitochondrial impairment
1339 Direct mitochondrial inhibition leads to Mitochondrial impairment
2083 Mitochondrial impairment leads to cell injury
1341 Mitochondrial impairment leads to Apoptosis
1342 Mitochondrial impairment leads to Necrosis
2577 Apoptosis leads to tumor growth
1867 Apoptosis leads to Activation, hepatic stellate cells
1869 Apoptosis leads to Liver Injury
1368 Apoptosis leads to Reproductive failure
2675 Apoptosis leads to Emphysema
2191 Apoptosis leads to Increase, Tissue/organ damage
2967 Apoptosis leads to N/A, Neurodegeneration
1713 Apoptosis leads to Testicular atrophy
1735 Apoptosis leads to Spermatocyte depletion
2792 Apoptosis leads to Decrease, outgrowth
1344 Increase, E75b expression leads to Increase, Ftz-f1 expression
1345 Increase, Ftz-f1 expression leads to Decrease, Circulating ETH
1347 Decrease, Circulating CCAP leads to Decrease, Ecdysis motoneuron bursts
1348 Decrease, Ecdysis motoneuron bursts leads to Decrease, Excitatory postsynaptic potential
1349 Decrease, Excitatory postsynaptic potential leads to Decrease, Abdominal muscle contraction
1351 Increase, COX-2 expression leads to Altered, Cardiovascular development/function
1353 Inactivation of PPARγ leads to Activation of TGF-β signaling
2156 Inactivation of PPARγ leads to Activation, TGF-beta pathway
1354 Activation of TGF-β signaling leads to Differentiation of Myofibroblast
1355 Activation of TGF-β signaling leads to Expression of Collagen
1721 Activation of TGF-β signaling leads to Increase, Inflammation
1723 Activation of TGF-β signaling leads to EMT
1356 Differentiation of Myofibroblast leads to Production of α-smooth muscle actin
1357 Expression of Collagen leads to Collagen Deposition
1358 Production of α-smooth muscle actin leads to Lung fibrosis
1359 Collagen Deposition leads to Lung fibrosis
1628 Collagen Deposition leads to Accumulation, Collagen
1361 ROS formation leads to Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK
1362 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Increased, DNA Damage-Repair
1363 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Damaging, Mitochondria
1364 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Activation, HIF-1
1365 Activation, HIF-1 leads to Apoptosis
1366 Increased, DNA Damage-Repair leads to Apoptosis
1369 Activation, JAK/STAT pathway leads to Activation, TGF-beta pathway
1370 Activation, TGF-beta pathway leads to Reproductive failure
2153 Activation, TGF-beta pathway leads to EMT
1371 Up Regulation, SREBF2 leads to Up Regulation, Unsaturated fatty acid
1372 Up Regulation, Unsaturated fatty acid leads to Perturbation of cholesterol
1373 Down Regulation, GSS and GSTs gene leads to Glutathione synthesis
1376 Down Regulation, GSS and GSTs gene leads to Glutathione homeostasis
1374 Glutathione synthesis leads to Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene
1375 Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene leads to Perturbation of cholesterol
1377 Perturbation of cholesterol leads to Hepatotoxicity
1378 Glutathione homeostasis leads to Hepatotoxicity
1380 Activation, JNK leads to Activation, FOXO
2149 Activation, JNK leads to AP-1 activation
2150 Activation, JNK leads to Pin-1 activation
1381 Activation, FOXO leads to Inhibition, Wnt pathway
1382 Inhibition, Wnt pathway leads to Defect of Embryogenesis
1383 Defect of Embryogenesis leads to Reproductive failure
1390 Increase, insulin leads to Activation, insulin receptor
1391 Activation, insulin receptor leads to Activation, mTORC2
1392 Activation, mTORC2 leads to Activation, AKT
1393 Activation, mTORC2 leads to Activation, mTORC1
1394 Activation, AKT leads to Activation, SREBP-1
1398 Activation, AKT leads to Activation, mTORC1
1400 Activation, AKT leads to Activation, L-FABP
1395 Activation, mTORC1 leads to Activation, L-FABP
1396 Activation, mTORC1 leads to Activation, HSD17B4
1399 Activation, mTORC1 leads to Activation, SREBP-1
1397 Activation, SREBP-1 leads to Activation, FXR
1403 Activation, SREBP-1 leads to Activation, SCD-1
1401 Activation, L-FABP leads to Increase, cytosolic fatty acid
1423 Activation, L-FABP leads to demethylation, PPARg promoter
1411 Activation, HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation
1415 Activation, HSD17B4 leads to Increase, Fatty acid β-oxidation
1407 Activation, FXR leads to Activation, SHP
1408 Activation, FXR leads to Activation, PPARα
1693 Increase, cytosolic fatty acid leads to steatohepatitis
1694 Increase, cytosolic fatty acid leads to Increased, Liver Steatosis
1405 Increased, lipogenesis leads to Increase, cytosolic fatty acid
1413 Inhibition, LXR leads to Inhibition, PPAR alpha
1421 Activation, aPKC leads to Activation, SREBP-1
1418 Activation, PI3K leads to Activation, AKT
1419 Activation, PI3K leads to Activation, L-FABP
1420 Activation, PI3K leads to Activation, aPKC
1416 Increase, Fatty acid β-oxidation leads to Inhibition, Steatosis
1417 Increase, Fatty acid β-oxidation leads to Decrease, cytosolic fatty acid
2217 Increase, Fatty acid β-oxidation leads to Decrease, Lipid storage
1425 Activation, LRH-1 leads to Activation, FAS
1520 Inhibit, serotonin transporter activity leads to Decreased, serotonin transporter activity
1426 Decreased, serotonin transporter activity leads to Increased, intracellular sodium (Na+)
1427 Decreased, serotonin transporter activity leads to Increased, intracellular chloride (Cl-)
1428 Decreased, serotonin transporter activity leads to Decreased, extracellular Na+
1429 Decreased, serotonin transporter activity leads to Decreased, extracellular chloride (Cl-)
1430 Decreased, serotonin transporter activity leads to Increased, extracellular serotonin
1431 Decreased, serotonin transporter activity leads to Decreased, intracellular serotonin
1521 Increased, extracellular serotonin leads to Decreased, extracellular serotonin
1529 Increased, extracellular serotonin leads to Decreased, 5-HT3
1531 Increased, extracellular serotonin leads to Activation, 5-HT2A
1455 Increased, intracellular sodium (Na+) leads to Activated, voltage-gated sodium channel
1465 Increased, intracellular chloride (Cl-) leads to Inactive, membrane depolarization
1432 Decreased, intracellular serotonin leads to Decreased, packaged serotonin
1433 Decreased, packaged serotonin leads to Decreased, synaptic release
1434 Decreased, synaptic release leads to Decreased, extracellular serotonin
1445 Increased, 5-HT3 leads to Increased, seizure
1446 Inactivated, 5-HTR leads to Reduce expression, BDNF
1511 Inactivated, 5-HTR leads to Reduced, BDNF
1447 Reduce expression, BDNF leads to Decreased, neuroplasticity
1448 Decreased, neuroplasticity leads to Increased, agitation
1449 Decreased, neuroplasticity leads to Increased, depression
1450 Increase, cortisone leads to Activation, Glucocorticoid Receptor
1523 Reduced, BDNF leads to Decreased, neuroplasticity
1438 Activation, 5-HT2A leads to Activate, PLC
1439 Activate, PLC leads to Increase, inositol triphosphate
1440 Increase, inositol triphosphate leads to Increase, intracellular calcium
2945 Increase, intracellular calcium leads to Increase, Mt Dysfunction
2954 Increase, intracellular calcium leads to Disruption, neurotransmitter release
2968 Increase, intracellular calcium leads to Apoptosis
1441 Increase, intracellular calcium leads to Activate, calmodulin
1442 Activate, calmodulin leads to Increase, myosin light chain phosphorylation
1443 Increase, myosin light chain phosphorylation leads to Increase, vascular smooth muscle contraction
1444 Increase, vascular smooth muscle contraction leads to Increase, hypertension
1581 Increase, hypertension leads to Respiratory irritability
1550 Increased, seizure leads to Increased, epilepsy
1435 Decreased, extracellular serotonin leads to Increased, 5-HT3
1436 Decreased, extracellular serotonin leads to Inactivated, 5-HTR
1437 Decreased, extracellular serotonin leads to Activation, 5-HT2A
1519 Decreased, extracellular serotonin leads to Decreased, synaptic release
1460 Increase, seizure leads to Increased, epilepsy
1452 Activated, presynaptic neuron 1 leads to Increased, glutamate
2861 Increased, glutamate leads to Microglia activation
2868 Increased, glutamate leads to decreased, Bcl-2
2869 Increased, glutamate leads to increased, Bax
1859 Increased, glutamate leads to Overactivation, NMDARs
1453 Increased, glutamate leads to Activated, NMDA receptor
1454 Activated, NMDA receptor leads to Increased, intracellular sodium (Na+)
1457 Activated, voltage-gated sodium channel leads to Activated, membrane depolarization
2605 Inhibit, voltage-gated sodium channel leads to Altered kinetics of sodium channel
1456 Treat, carbamazepine leads to Inhibit, voltage-gated sodium channel
1458 Activated, membrane depolarization leads to Increased, hippocampal hyperdepolarization
1555 Increased, RDX dose leads to Reduced, GABA-A receptor activation
1463 Increased, RDX dose leads to Activate, GABA-A receptor
1464 Activate, GABA-A receptor leads to Increased, intracellular chloride (Cl-)
1461 Activate, presynaptic neuron 2 leads to Increase, GABA
1462 Increase, GABA leads to Activate, GABA-A receptor
1549 Increased, hippocampal hyperdepolarization leads to Increased, seizure
1459 Increased, hippocampal hyperdepolarization leads to Increase, seizure
2826 Increase, ROS leads to Oxidative Stress
2342 Increase, ROS leads to D1 protein deactivation
2345 Increase, ROS leads to Decrease, MMP
1595 Increase, ROS leads to Increase, DNA Damage
1598 Increase, ROS leads to Increased, LPO
1876 Increase, ROS leads to Increase,Oxidative DNA damage
1466 Increase, ROS leads to Peptide Oxidation
2075 Increase, Apoptosis leads to Reduce, Sperm count
2602 Increase, Apoptosis leads to Microcephaly
2619 Increase, Apoptosis leads to Decreased spermatogenesis
1596 Increase, Apoptosis leads to Increase, Follicular atresia
2645 Increase, Apoptosis leads to Occurrence, renal proximal tubular necrosis
2948 Increase, Apoptosis leads to Inhibition of neurotransmitter release
2185 Increase, Apoptosis leads to Increase, Tissue/organ damage
2461 Increase, Apoptosis leads to Increased, Kidney Failure
2725 Increase, Apoptosis leads to Decrease, outgrowth
1469 Increase, Apoptosis leads to Decrease, Oogenesis
1741 Increase, Apoptosis leads to Decrease, Growth
1751 Increase, Apoptosis leads to Increase, Mortality
3034 Increase, Apoptosis leads to increased，Vascular endothelial dysfunction
2586 Decrease, Oogenesis leads to Decrease, Reproduction
2588 Decrease, Oogenesis leads to Reduction, Cumulative fecundity and spawning
1470 Decrease, Oogenesis leads to Decrease, Ovulation
1752 Decrease, Oogenesis leads to Decrease, Fecundity
1480 Activation, PTGS-1 leads to Increase, platelet aggregation
1481 Activation, PTGS-1 leads to Increase, mucosal blood flow
1482 Activation, PTGS-1 leads to Increase, mucous
1483 Activation, PTGS-1 leads to Increase, bicarbonate
1478 Activation, PTGS-2 leads to Decrease, leukocyte adherence
1479 Activation, PTGS-2 leads to Increase, angiogenesis
1484 Increase, bicarbonate leads to Activate, mucosal defense
1485 Increase, mucous leads to Activate, mucosal defense
1486 Increase, mucosal blood flow leads to Activate, mucosal defense
1474 Increase, platelet aggregation leads to Inhibit, gastric ulcer formation
2578 Increase, angiogenesis leads to N/A, Breast Cancer
1473 Increase, angiogenesis leads to Inhibit, gastric ulcer formation
1477 Increase, leukocyte adherence leads to Activate, leukocyte
1476 Activate, leukocyte leads to Activated, gastric ulcer formation
1475 Activate, mucosal defense leads to Inhibit, gastric ulcer formation
1489 Increase, surfactant leads to Activate, mucosal defense
1547 Decrease, surfactant leads to Reduced, mucosal defense
1488 Activate, phospholipase leads to Decrease, surfactant
1487 Increase, ammonium (NH4+) leads to Decrease, surfactant
1493 CYP7B activity, inhibition leads to 7α-hydroxypregnenolone synthesis in the brain, decreased
1494 CYP7B activity, inhibition leads to Locomotor activity, decreased
1495 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Locomotor activity, decreased
1496 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Dopamine release in the brain, decreased
1498 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Sexual behavior, decreased
1497 Dopamine release in the brain, decreased leads to Locomotor activity, decreased
1502 Dopamine release in the brain, decreased leads to Sexual behavior, decreased
1500 Locomotor activity, decreased leads to Decreased, Reproductive Success
1499 Sexual behavior, decreased leads to Decreased, Reproductive Success
2654 Activation of Cyp2E1 leads to Oxidative Stress in Brain
1512 Activation of Cyp2E1 leads to Oxidative Stress
1515 Activation of Cyp2E1 leads to Hepatocytotoxicity
2818 Oxidative Stress leads to Cataracts
2827 Oxidative Stress leads to Mitochondrial dysfunction
2833 Oxidative Stress leads to Tissue resident cell activation
2846 Oxidative Stress leads to Altered Bone Cell Homeostasis
2674 Oxidative Stress leads to Pulmonary inflammation
2449 Oxidative Stress leads to CFTR Function, Decreased
2450 Oxidative Stress leads to FOXJ1 Protein, Decreased
2451 Oxidative Stress leads to CBF, Decreased
1685 Oxidative Stress leads to Glutamate dyshomeostasis
1690 Oxidative Stress leads to Cell injury/death
2714 Oxidative Stress leads to Mitochondrial Injury
2716 Oxidative Stress leads to Increase, Cell death
2975 Oxidative Stress leads to Increase, Inflammation
2505 Oxidative Stress leads to p-Tau
2771 Oxidative Stress leads to Altered Signaling
2772 Oxidative Stress leads to Increased pro-inflammatory mediators
2774 Oxidative Stress leads to Altered, Nitric Oxide Levels
2008 Oxidative Stress leads to Wnt ligand stimulation
2776 Oxidative Stress leads to Increase, Endothelial Dysfunction
3047 Oxidative Stress leads to Accumulation, misfolded proteins
3048 Oxidative Stress leads to Proteasomal dysfunction
1513 Oxidative Stress leads to Hepatocytotoxicity
1516 Oxidative Stress leads to Liver Cancer
2289 Oxidative Stress leads to Coagulation
2810 Oxidative Stress leads to Increase, Oxidative DNA damage
2811 Oxidative Stress leads to Increase, DNA strand breaks
2812 Oxidative Stress leads to Modified Proteins
1514 Hepatocytotoxicity leads to Sustained proliferation
1517 Hepatocytotoxicity leads to Liver Cancer
1518 Sustained proliferation leads to Liver Cancer
1522 Increased, glucocorticoid receptor activity leads to Reduced, BDNF
1524 Increased, serotonin transporter activity leads to Increased, intracellular serotonin
1528 Increased, serotonin transporter activity leads to Decreased, extracellular serotonin
1525 Increased, intracellular serotonin leads to Increased, packaged serotonin
1526 Increased, packaged serotonin leads to Increased, synaptic release
1527 Increased, synaptic release leads to Increased, extracellular serotonin
1530 Decreased, 5-HT3 leads to Increased, seizure
1537 Reduced, PTGS1 function leads to Decreased, mucous
1539 Reduced, PTGS1 function leads to Decreased, bicarbonate
1532 Reduced, PTGS1 function leads to Reduced, platelet aggregation
1534 Reduced, PTGS1 function leads to Decreased, mucosal blood flow
1533 Reduced, platelet aggregation leads to Activated, gastric ulcer formation
1535 Decreased, mucosal blood flow leads to Reduced, mucosal defense
1536 Reduced, mucosal defense leads to Activated, gastric ulcer formation
1548 Reduced, mucosal defense leads to Helicobacter pylori infection
1538 Decreased, mucous leads to Reduced, mucosal defense
1540 Decreased, bicarbonate leads to Reduced, mucosal defense
1541 Reduced, PTGS2 function leads to Decreased, angiogenesis
1543 Reduced, PTGS2 function leads to Increased, leukocyte adherence
1542 Decreased, angiogenesis leads to Activated, gastric ulcer formation
1544 Increased, leukocyte adherence leads to Increased, leukocyte activation
1545 Increased, leukocyte activation leads to Activated, gastric ulcer formation
1546 Helicobacter pylori infection leads to Increase, ammonium (NH4+)
1551 Reduced, presynaptic neuron 2 activity leads to Decreased, GABA
1552 Decreased, GABA leads to Reduced, GABA-A receptor activation
1553 Reduced, GABA-A receptor activation leads to Decreased, intracellular chloride
1554 Decreased, intracellular chloride leads to Activated, membrane depolarization
1556 NFE2/Nrf2 repression leads to Reduced, FXR activity
2979 NFE2/Nrf2 repression leads to Increase, Oxidative Stress
2984 NFE2/Nrf2 repression leads to Activation, HIF1α
3035 NFE2/Nrf2 repression leads to Activation, inflammation pathway
1557 Reduced, FXR activity leads to Reduced, SHP activity
1558 Reduced, SHP activity leads to Activated, LXR
1559 Activated, LXR leads to Reduced, PPARalpha
1560 Reduced, PPARalpha leads to Reduced, HSD17B4 activity
1561 Reduced, HSD17B4 activity leads to Reduced, fatty acid beta oxidation
1562 Reduced, fatty acid beta oxidation leads to Increased, steatosis
1563 Mu Opioid Receptor Agonism leads to Release of G Proteins
1564 Release of G Proteins leads to Opening of GIRK channels
1568 Release of G Proteins leads to Inhibition of Ca Channels
1565 Opening of GIRK channels leads to hyperpolarisation, neuron
1569 Inhibition of Ca Channels leads to Inhibition of neurotransmitter release
1570 Inhibition of neurotransmitter release leads to Analgesia
1573 Inhibition of neurotransmitter release leads to Anti-depressant Activity
1571 Serotonin 1A Receptor Agonism leads to Release of G Proteins
1579 Increased CGRP leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1580 Increased CGRP leads to Increase, hypertension
1586 Increased CGRP leads to Leukocyte infiltration
1587 Increased CGRP leads to Respiratory irritability
1774 Irritation induced sneezing leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1584 Increased NKA leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1585 Increased NKA leads to Leukocyte infiltration
1773 Increased NKA leads to Respiratory irritability
1588 Sensing of the stressor leads to Increased transcription of APP
1589 Increased transcription of APP leads to Systemic APR
2860 Systemic APR leads to Atherosclerosis
1590 Systemic APR leads to HDL-SAA formation
1591 HDL-SAA formation leads to Systemic cholesterol increased
1593 HDL-SAA formation leads to Foam cell formation
1592 Systemic cholesterol increased leads to Foam cell formation
1594 Foam cell formation leads to Atherosclerosis
1597 Increase, Follicular atresia leads to Decrease, Oogenesis
2211 Increase, Follicular atresia leads to Decrease, Fecundity
2097 Increased, LPO leads to Decrease, Neutral lipids
1599 Increased, LPO leads to Decrease, Coupling of OXPHOS
2879 Increased, LPO leads to impaired, Fertility
2206 Increased, LPO leads to Decrease, Lipid storage
2464 Increased, LPO leads to Increase, Necrosis
2210 Increased, LPO leads to Increase, Apoptosis
2222 Increased, LPO leads to Increase, Cell death
1600 Decrease, Coupling of OXPHOS leads to Decrease, Mitochondrial ATP production
2175 Decrease, Coupling of OXPHOS leads to Decrease, ATP synthase activity
2182 Decrease, Coupling of OXPHOS leads to Increase, Complex III dysfunction
2188 Decrease, Coupling of OXPHOS leads to Increase, Complex I dysfunction
2203 Decrease, Coupling of OXPHOS leads to Decrease, ATP pool
2219 Decrease, Coupling of OXPHOS leads to Increase, Oxygen consumption
2763 Decrease, Coupling of OXPHOS leads to Increase, Cytosolic Ca
2793 Decrease, Coupling of OXPHOS leads to Increase, Glycolysis
2796 Decrease, Coupling of OXPHOS leads to Increase, Mitochondrial swelling
1610 activation of CEBPA leads to Activation of specific nuclear receptors, PPAR-gamma activation
1611 activation of CEBPA leads to increased adipogenesis
1612 increased adipogenesis leads to obesity
1614 decreased dopamine leads to decreased reward
1615 decreased reward leads to decreased DNA methylation of tyrosine hydroxylase
1616 decreased reward leads to decreased methylation of dopamine transporter promoter
1617 decreased reward leads to decreased dopamine
1618 decreased DNA methylation of tyrosine hydroxylase leads to obesity
1620 decreased DNA methylation of tyrosine hydroxylase leads to decreased dopamine
1619 decreased methylation of dopamine transporter promoter leads to obesity
1621 decreased methylation of dopamine transporter promoter leads to decreased dopamine
1613 chronic high fat diet leads to decreased dopamine
1622 Sustained inflammatory cytokine release leads to Increased, secretion of local growth factors
1633 Sustained inflammatory cytokine release leads to Differentiation of fibroblasts
1626 Differentiation of fibroblasts leads to Expression of Collagen
1654 Differentiation of fibroblasts leads to Accumulation, Collagen
1840 EMT leads to Fibroproliferative airway lesions
2614 EMT leads to Metastasis, Breast Cancer
1627 EMT leads to Expression of Collagen
2154 EMT leads to Pulmonary fibrosis
1655 EMT leads to Accumulation, Collagen
1725 EMT leads to Lung fibrosis
1779 EMT leads to Collagen Deposition
1630 Cell damage sensing leads to Sustained inflammatory cytokine release
1631 Cell damage sensing leads to Increase, ROS production
1632 Cell damage sensing leads to Increased, secretion of local growth factors
1635 DSB leads to MLL translocation
1636 Thiol protein adducts leads to Inhibition of lysyl oxidase
1637 Inhibition of lysyl oxidase leads to Reduction of collagen crosslinking
1638 Reduction of collagen crosslinking leads to Weak collagen matrix
1639 Weak collagen matrix leads to Notochord malformation
1640 Notochord malformation leads to Reduced, Swimming performance
1651 TGFbeta1 activation leads to TGFbeta pathway activation
1652 TGFbeta pathway activation leads to Differentiation of fibroblasts
1653 TGFbeta pathway activation leads to EMT
1663 Increase, Uncoupling of photophosphorylation leads to Decrease, ATP production
2341 Decrease, ATP production leads to Decrease, Leaf development
1664 Decrease, ATP production leads to Decrease, Chlorophyll synthesis
2547 Decrease, ATP production leads to Decrease, Reproduction
1665 Decrease, Chlorophyll synthesis leads to Decrease, Light harvest capacity
1666 Decrease, Light harvest capacity leads to Decrease, Photosynthesis
2334 Decrease, Photosynthesis leads to Decrease, ATP production
2343 Decrease, Photosynthesis leads to Decrease, ATP synthase activity
1667 Decrease, Photosynthesis leads to Decrease, Glycolysis
1668 Decrease, Glycolysis leads to Decrease, OXPHOS
1738 Decrease, Glycolysis leads to Decrease, Mitochondrial ATP production
1810 Decrease, OXPHOS leads to Decreased Na/K ATPase activity
2346 Decrease, OXPHOS leads to Decrease, ATP synthase activity
2095 Decrease, OXPHOS leads to Decrease, ATP pool
1669 Decrease, OXPHOS leads to Decrease, Mitochondrial ATP production
2713 Decrease, OXPHOS leads to Oxidative Stress
1671 Decrease, Leaf cell mitosis leads to Decrease, Leaf development
2335 Decrease, Leaf development leads to Decrease, Reproduction
1672 Decrease, Leaf development leads to Increase, Growth hormone
2283 Decrease, Leaf development leads to Decrease, Growth
1673 Inhibition, mitochondrial DNA polymerase gamma (Pol gamma) leads to Depletion, mtDNA
1674 Depletion, mtDNA leads to Dysfunction, Mitochondria
1675 Dysfunction, Mitochondria leads to Increase, Cytotoxicity (renal tubular cell)
1681 Dysfunction, Mitochondria leads to Decrease, Mitochondrial ATP production
1677 Binding of substrate, endocytic receptor leads to Disturbance, Lysosomal function
1683 Binding, SH/SeH proteins involved in protection against oxidative stress leads to N/A, Mitochondrial dysfunction 1
1689 Binding, SH/SeH proteins involved in protection against oxidative stress leads to Oxidative Stress
1765 Binding, SH/SeH proteins involved in protection against oxidative stress leads to Protection against oxidative stress, decreased
1686 Glutamate dyshomeostasis leads to Cell injury/death
1691 Glutamate dyshomeostasis leads to Neuronal network function, Decreased
1692 Inhibition of fatty acid beta oxidation leads to Increase, cytosolic fatty acid
1697 increased, oncotic necrosis leads to steatohepatitis
2834 Tissue resident cell activation leads to Increase, Pro-Inflammatory Mediators
1763 Tissue resident cell activation leads to Increased pro-inflammatory mediators
1902 Increased pro-inflammatory mediators leads to N/A, Breast Cancer
1903 Increased pro-inflammatory mediators leads to Increase in RONS
1908 Increased pro-inflammatory mediators leads to Increase, Cell Proliferation (Epithelial Cells)
1719 Increased pro-inflammatory mediators leads to Cell injury/death
2777 Increased pro-inflammatory mediators leads to Increase, Endothelial Dysfunction
1764 Increased pro-inflammatory mediators leads to Activation, Stellate cells
1777 Increased pro-inflammatory mediators leads to Leukocyte recruitment/activation
2891 Leukocyte recruitment/activation leads to Increased extracellular matrix deposition
1901 Leukocyte recruitment/activation leads to Increase, Cell Proliferation (Epithelial Cells)
1905 Leukocyte recruitment/activation leads to Increase in RONS
1778 Leukocyte recruitment/activation leads to Activation, Stellate cells
2662 Interaction with the lung cell membrane leads to Increased, Reactive oxygen species
2663 Interaction with the lung cell membrane leads to Increased, DNA damage and mutation
2958 Interaction with the lung cell membrane leads to Increased transcription of APP
2959 Interaction with the lung cell membrane leads to Systemic APR
2960 Interaction with the lung cell membrane leads to Atherosclerosis
1702 Interaction with the lung cell membrane leads to Increased proinflammatory mediators
2307 Increased proinflammatory mediators leads to Accumulation, Collagen
2053 Increased proinflammatory mediators leads to Increased transcription of APP
2061 Increased proinflammatory mediators leads to Increased inflammatory immune responses
2651 Increased proinflammatory mediators leads to Activation, Dendritic Cells
1703 Increased proinflammatory mediators leads to Recruitment of inflammatory cells
3052 Increased proinflammatory mediators leads to Systemic APR
2301 Increased proinflammatory mediators leads to Impaired gustatory nerve
2354 Recruitment of inflammatory cells leads to Hyperinflammation
2903 Recruitment of inflammatory cells leads to Increase in inflammation
2658 Recruitment of inflammatory cells leads to Increase, Cytotoxicity (epithelial cells)
1704 Recruitment of inflammatory cells leads to Loss of alveolar capillary membrane integrity
1964 Recruitment of inflammatory cells leads to Increased, Reactive oxygen species
2491 Recruitment of inflammatory cells leads to Disruption of the intestinal barrier
2492 Recruitment of inflammatory cells leads to GI disorders
2761 Recruitment of inflammatory cells leads to Increased proinflammatory mediators
2543 Recruitment of inflammatory cells leads to Gut dysbiosis
2368 Loss of alveolar capillary membrane integrity leads to Inhibition of LS function.
2369 Loss of alveolar capillary membrane integrity leads to Reduced tidal volume
2372 Loss of alveolar capillary membrane integrity leads to Decreased lung function
2174 Loss of alveolar capillary membrane integrity leads to Blood extravasation into the lungs
1705 Loss of alveolar capillary membrane integrity leads to Activation of Th2 cells
2258 Loss of alveolar capillary membrane integrity leads to Impaired lung function
2259 Loss of alveolar capillary membrane integrity leads to Substance - LS interaction
1706 Activation of Th2 cells leads to Increased cellular proliferation and differentiation
2652 Increased cellular proliferation and differentiation leads to Accumulation, Collagen
1707 Increased cellular proliferation and differentiation leads to Increased extracellular matrix deposition
2325 Increased extracellular matrix deposition leads to N/A, Liver fibrosis
1708 Increased extracellular matrix deposition leads to Pulmonary fibrosis
1802 Histone deacetylase inhibition leads to Reduced neural crest cell migration
1805 Histone deacetylase inhibition leads to Reduced collagen production
2699 Histone deacetylase inhibition leads to Neural tube defects
1709 Histone deacetylase inhibition leads to Histone acetylation, increase
1714 Histone deacetylase inhibition leads to p21 (CDKN1A) expression, increase
1715 Histone deacetylase inhibition leads to Cell cycle, disrupted
1716 Histone deacetylase inhibition leads to Apoptosis
1717 Histone deacetylase inhibition leads to Testicular atrophy
2010 Histone deacetylase inhibition leads to Spermatocyte depletion
1806 Histone acetylation, increase leads to Altered, Gene Expression
1710 Histone acetylation, increase leads to p21 (CDKN1A) expression, increase
1997 Histone acetylation, increase leads to Cell cycle, disrupted
1711 p21 (CDKN1A) expression, increase leads to Cell cycle, disrupted
1712 Cell cycle, disrupted leads to Apoptosis
2791 Cell cycle, disrupted leads to Altered, Meiotic chromosome dynamics
1720 Activation of PPARγ leads to Increase, Inflammation
1726 CYP2E1 Activation leads to Oxidative Stress in Brain
1729 Protein Adduct Formation leads to Unfolded Protein Response
2655 Oxidative Stress in Brain leads to N/A, Neurodegeneration
2952 Oxidative Stress in Brain leads to Neuronal network function, Decreased
1727 Oxidative Stress in Brain leads to Lipid Peroxidation
1730 Oxidative Stress in Brain leads to Unfolded Protein Response
1728 Lipid Peroxidation leads to Protein Adduct Formation
1731 Lipid Peroxidation leads to General Apoptosis
1866 Unfolded Protein Response leads to Apoptosis
2712 Unfolded Protein Response leads to Increase, Cell death
1732 Unfolded Protein Response leads to General Apoptosis
3041 Unfolded Protein Response leads to Caspase activation
2977 General Apoptosis leads to Increase, Cancer
1733 General Apoptosis leads to Neurodegeneration
1734 Spermatocyte depletion leads to Testicular atrophy
1736 Increase, D1 protein antagonism leads to Decrease, PSII activity
1737 Decrease, PSII activity leads to Decrease, Photosynthesis
1740 Decrease, PSII activity leads to Increase, ROS
2169 Decrease, Growth leads to Decrease, Population growth rate
2804 Decrease, Growth leads to Decreased, Reproductive Success
1742 Inhibition, CHS-1 leads to Decrease, Cuticular chitin content
1743 Decrease, Cuticular chitin content leads to Increase, Premature molting
1744 Increase, Premature molting leads to Increase, Mortality
1745 Increase, SUR binding leads to Increase, Cell membrane depolarization
1747 Increase, Opening of voltage-dependent calcium channel leads to Decrease, Cuticular chitin content
2708 Increase, Cell membrane depolarization leads to Increased, Intracellular Calcium overload
1746 Increase, Cell membrane depolarization leads to Increase, Opening of voltage-dependent calcium channel
3039 Increase, Cell membrane depolarization leads to Opening VGCCs
2788 Increase, Cell membrane depolarization leads to Cell injury/death
1749 Fatty Acid Beta Oxidation, Decreased leads to Decreased, Ketogenesis (production of ketone bodies)
1755 Blockade, L-Type Calcium Channels leads to Decrease, Calcium currents
1756 Decrease, Calcium currents leads to Decrease, Calcium binding to Troponin C
1760 Decrease, Calcium currents leads to Disruption, Intracellular calcium mobilization
1757 Decrease, Calcium binding to Troponin C leads to Decrease, Cardiac contractility
2824 Decrease, Cardiac contractility leads to Heart failure
1758 Decrease, Cardiac contractility leads to Decrease, Cardiac ejection fraction
1759 Decrease, Cardiac ejection fraction leads to Heart failure
2825 Heart failure leads to Increase, Mortality
2508 Heart failure leads to Upregulation of ACE2
2514 Heart failure leads to Altered mechanotransduction properties of pericytes
1761 Disruption, Intracellular calcium mobilization leads to Disruption, Sarcomere assembly
1762 Disruption, Sarcomere assembly leads to Decrease, Cardiac contractility
1766 Protection against oxidative stress, decreased leads to Oxidative Stress
1775 endocytosis leads to Disruption, Lysosome
1780 Mitochondrial Complex I inhibition leads to Decrease in mitochondrial oxidative phosphorylation
1790 Mitochondrial Complex I inhibition leads to Increased reactive oxygen species (in the mitochondria)
1872 Increase, Mitochondrial complex III antagonism leads to Decrease, OXPHOS
1875 Increase, Mitochondrial complex III antagonism leads to Increase, ROS
2230 Increase, Mitochondrial complex III antagonism leads to Decrease, ATP pool
1781 Increase, Mitochondrial complex III antagonism leads to Decrease in mitochondrial oxidative phosphorylation
1784 Increase, Mitochondrial complex III antagonism leads to Increased reactive oxygen species (in the mitochondria)
1782 Mitochondrial Complex IV inhibition leads to Decrease in mitochondrial oxidative phosphorylation
1785 Mitochondrial Complex IV inhibition leads to Increased reactive oxygen species (in the mitochondria)
1783 Mitochondrial Complex V inhibition leads to Decrease in mitochondrial oxidative phosphorylation
1786 Mitochondrial Complex V inhibition leads to Increased reactive oxygen species (in the mitochondria)
1956 Decrease in mitochondrial oxidative phosphorylation leads to N/A, Mitochondrial dysfunction 1
1787 Decrease in mitochondrial oxidative phosphorylation leads to Mitochondrial Injury
1957 Increased reactive oxygen species (in the mitochondria) leads to N/A, Mitochondrial dysfunction 1
1788 Increased reactive oxygen species (in the mitochondria) leads to Mitochondrial Injury
1941 Mitochondrial Injury leads to Increased reactive oxygen species (in the mitochondria)
1942 Mitochondrial Injury leads to Impaired, Proteostasis
2715 Mitochondrial Injury leads to Increase, Cell death
3049 Mitochondrial Injury leads to Increase, Cyt c release
1789 Necrotic Tissue leads to Liver Injury
1798 Ionizing Energy leads to Increase mutations
1799 Ionizing Energy leads to Increase chromosomal aberrations
2379 Ionizing Energy leads to Increased, Reactive oxygen species
2380 Ionizing Energy leads to Increase, DNA Damage
2390 Ionizing Energy leads to Increased, Oxidative Stress
2392 Ionizing Energy leads to Altered, Meiotic chromosome dynamics
2393 Ionizing Energy leads to Decreased spermatogenesis
2394 Ionizing Energy leads to impaired, Fertility
2395 Ionizing Energy leads to Decrease of egg production and cummulative fecundity
2396 Ionizing Energy leads to Decreased, Population size
2397 Ionizing Energy leads to Increase, Oocyte apoptosis
1791 Ionizing Energy leads to DNA DNA double strand breaks
1792 DNA DNA double strand breaks leads to DNA repair
1793 DNA repair leads to Increase mutations
1794 DNA repair leads to Increase chromosomal aberrations
1795 Increase mutations leads to Increase cell proliferation
1800 Increase mutations leads to Increase, lung cancer
1900 Increase mutations leads to Increase, Cell Proliferation (Epithelial Cells)
1796 Increase chromosomal aberrations leads to Increase cell proliferation
1801 Increase chromosomal aberrations leads to Increase, lung cancer
2729 Increase chromosomal aberrations leads to Increase,miRNA levels
1797 Increase cell proliferation leads to Increase, lung cancer
2563 Reduced neural crest cell migration leads to Transposition of the great arteries
1803 Reduced neural crest cell migration leads to Reduced collagen production
1804 Reduced collagen production leads to Smaller and morphologically distorted facial cartilage structures
2686 Smaller and morphologically distorted facial cartilage structures leads to Increase, Early Life Stage Mortality
1808 Altered differentiation leads to Neural tube defects
2603 Altered differentiation leads to Microcephaly
1811 Decreased Na/K ATPase activity leads to Decreased proximal tubular vectorial transport
2787 Decreased Na/K ATPase activity leads to Increase, Cell membrane depolarization
1812 Decreased proximal tubular vectorial transport leads to Chemical induced Fanconi syndrome
1817 Suppressed AP-1 leads to Suppressed DC activation
1818 Suppressed NF-kB leads to Suppressed DC activation
1819 Suppressed DC activation leads to Impaired antigen presentation
1820 Impaired antigen presentation leads to Impaired T cell activation
1821 Impaired T cell activation leads to Suppression, Suppression of T-cell dependent antibody response (TDAR)
1822 Impaired T cell activation leads to Impairment of TDAR
1922 Impaired T cell activation leads to Impaired Ab production
1813 Blocking of IL-1R leads to Impaired IL-1 signaling
1814 Decreased IL-1 production leads to Impaired IL-1 signaling
1824 Decreased IL-1 production leads to Suppressed MyD88
1815 Impaired IL-1 signaling leads to Suppressed AP-1
1816 Impaired IL-1 signaling leads to Suppressed NF-kB
1825 Impaired IL-1 signaling leads to Suppressed MyD88
1920 Impaired IL-1 signaling leads to Inhibition, Nuclear factor kappa B (NF-kB)
1826 Suppressed MyD88 leads to Impairment of TDAR
1870 Suppressed MyD88 leads to Inhibition, Nuclear factor kappa B (NF-kB)
1827 Inhibition, IKK complex leads to Inhibition, Nuclear factor kappa B (NF-kB)
1829 Activation, Caspase 8 pathway leads to Cell injury/death
1832 Activation, Tissue resident cells (Kuppfer cells) leads to Increase, proinflammatory mediators (TNFalpha)
1833 Binding of MSAs to microtubules leads to Disturbance in microtubule dynamic instability
1834 Disturbance in microtubule dynamic instability leads to Impaired axonial transport
1835 Impaired axonial transport leads to Sensory axonal peripheral neuropathy
2506 Impaired axonial transport leads to Dysfunctional synapses
2657 Sensory axonal peripheral neuropathy leads to Increased Mortality
1836 Interaction of α-diketones with arginine residues leads to Proteasomal dysfunction
1837 Proteasomal dysfunction leads to Airway epithelial injury
3044 Proteasomal dysfunction leads to Accumulation, misfolded proteins
1838 Airway epithelial injury leads to Increase, Inflammation
1841 Fibroproliferative airway lesions leads to Bronchiolitis obliterans
1842 Distribution of chemicals leads to Absorption of photon energy
1843 Absorption of photon energy leads to ROS generation
1844 Absorption of photon energy leads to Radical generation
1845 ROS generation leads to Oxidation of membrane lipids
1846 ROS generation leads to Oxidation/denatuation of membrane proteins
1847 ROS generation leads to Oxidation of DNA
1848 Radical generation leads to DNA photo-adducts
1849 Radical generation leads to Protein photo-adducts
1850 Oxidation of membrane lipids leads to Inflammatory events
1851 Oxidation/denatuation of membrane proteins leads to Inflammatory events
1852 Oxidation of DNA leads to Inflammatory events
1853 DNA photo-adducts leads to Inflammatory events
1854 Protein photo-adducts leads to Inflammatory events
1855 Inflammatory events leads to Eczematous eruption
2916 Inflammatory events leads to Increased, Invasion
2917 Inflammatory events leads to prostatic intraepithelial neoplasia
1856 Eczematous eruption leads to Scaling, Lichenification
1858 Activation, Muscarinic Acetylcholine Receptors leads to Increased, glutamate
1889 Activation, Muscarinic Acetylcholine Receptors leads to Occurrence, Focal Seizure
1864 Inhibition of N-linked glycosylation leads to Accumulation, misfolded proteins
1865 Accumulation, misfolded proteins leads to Unfolded Protein Response
3045 Accumulation, misfolded proteins leads to Endoplasmic reticulum stress
3046 Accumulation, misfolded proteins leads to Caspase activation
1868 Activation, hepatic stellate cells leads to Liver Injury
2122 Increase, Necrosis leads to Increase, Ovarian follicle breakdown
1874 Increase, Necrosis leads to Increase, Mortality
2177 Increase, Necrosis leads to Increase, Tissue/organ damage
2465 Increase, Necrosis leads to Increased, Kidney Failure
2100 Increase,Oxidative DNA damage leads to Increase, DNA DSB
1877 Increase,Oxidative DNA damage leads to Increase, Apoptosis
2190 Increase,Oxidative DNA damage leads to Apoptosis
2221 Increase,Oxidative DNA damage leads to Increase, Cell death
2558 Increase,Oxidative DNA damage leads to Increase, Oocyte apoptosis
2559 Increase,Oxidative DNA damage leads to Increase, Ovarian somatic cell apoptosis
1878 Inhibition of Cyp17A1 activity leads to Reduction, DHEA
1879 Inhibition of Cyp17A1 activity leads to Reduction, androstenedione
1932 Reduction, DHEA leads to Decrease, testosterone level
1933 Reduction, androstenedione leads to Decrease, testosterone level
1934 Decrease, testosterone level leads to Decrease, DHT level
1936 Decrease, testosterone level leads to Decrease, AR activation
1881 Decrease, DHT level leads to Reduction, Plasma 17beta-estradiol concentrations
1935 Decrease, DHT level leads to Decrease, AR activation
2820 Decrease, AR activation leads to AGD, decreased
2828 Decrease, AR activation leads to Hypospadias
2124 Decrease, AR activation leads to Altered, Transcription of genes by AR
2128 Decrease, AR activation leads to decrease, transcription of genes by AR
1937 Decrease, AR activation leads to Impaired inguinoscrotal phase
1938 Impaired inguinoscrotal phase leads to Malformation, cryptorchidism
1880 Inhibition, 5α-reductase leads to Decrease, DHT level
2101 Increase, DNMT inhibition leads to Decrease, Global DNA methylation
2108 Increase, DNMT inhibition leads to Increase, DNA DSB
1883 Increase, DNMT inhibition leads to Increase, DNA hypomethylation
1884 Increase, DNA hypomethylation leads to Increase, Gene expression
1887 Increase, DNA hypomethylation leads to Decrease, Transgenerational DNA methylation
1885 Increase, Gene expression leads to Decrease, Fecundity
1888 Decrease, Transgenerational DNA methylation leads to Increase, Gene expression
1890 Occurrence, Focal Seizure leads to Increased, glutamate
1998 Occurrence, Focal Seizure leads to Overactivation, NMDARs
1891 tyrosinase leads to Reduction of L-Dopaquinone
1892 Reduction of L-Dopaquinone leads to Reduction in melanin level
1893 Reduction in melanin level leads to Reduction of melanosome level
1894 Reduction of melanosome level leads to Reduction fo Pigmentation pattern
1895 Reduction fo Pigmentation pattern leads to Decrease, Population growth rate
2331 Increase in RONS leads to D1 protein deactivation
2337 Increase in RONS leads to Decrease, MMP
2617 Increase in RONS leads to Increased, Oxidative Stress
1904 Increase in RONS leads to Increase, DNA Damage
1906 Increase in RONS leads to Tissue resident cell activation
2798 Increase in RONS leads to methemocyanin formation (decrease overall oxygen binding capacity)
2646 Increase in inflammation leads to Occurrence, renal proximal tubular necrosis
2904 Increase in inflammation leads to Insulin resistance
2199 Increase in inflammation leads to hepatitis
2591 Increase, Oxidative DNA damage leads to Increase, Follicular atresia
2592 Increase, Oxidative DNA damage leads to Increase, Oocyte apoptosis
1909 Increase, Oxidative DNA damage leads to Inadequate DNA repair
1913 Increase, Oxidative DNA damage leads to Increase, DNA strand breaks
1914 Increase, Oxidative DNA damage leads to Increase, Mutations
2841 Increase, DNA strand breaks leads to Increase, Neural Remodeling
2074 Increase, DNA strand breaks leads to Increase, Apoptosis
2587 Increase, DNA strand breaks leads to Increase, Follicular atresia
2589 Increase, DNA strand breaks leads to Increase, Oocyte apoptosis
2856 Increase, DNA strand breaks leads to Altered Signaling
1911 Increase, DNA strand breaks leads to Inadequate DNA repair
1931 Increase, DNA strand breaks leads to Increase, Mutations
1939 Increase, DNA strand breaks leads to Increase, Chromosomal aberrations
1979 Increase, Chromosomal aberrations leads to Increase, Cell Proliferation
1985 Increase, Chromosomal aberrations leads to Increase, lung cancer
1915 Retinaldehyde dehydrogenase leads to retinoic acid
1918 Altered, Photoreceptor patterning leads to Altered, Visual function
1916 retinoic acid leads to plasma retionic acid
1917 plasma retionic acid leads to Altered, Photoreceptor patterning
2375 Altered, Visual function leads to Increased Mortality
2143 Altered, Visual function leads to Decrease, Population growth rate
1919 Altered, Visual function leads to Decline, Population
1923 Impaired Ab production leads to Impairment of TDAR
1924 Wnt ligand stimulation leads to Frizzled activation
1925 Frizzled activation leads to GSK3beta inactivation
1926 GSK3beta inactivation leads to β-catenin activation
2485 GSK3beta inactivation leads to Repression of Gbx2 expression
1927 β-catenin activation leads to Snail, Zeb, Twist activation
1928 Snail, Zeb, Twist activation leads to Epithelial-mesenchymal transition
2677 Epithelial-mesenchymal transition leads to Airway remodeling
1929 Epithelial-mesenchymal transition leads to Resistant gastric cancer
1930 Increase, SAM depletion leads to Increase, DNA hypomethylation
1944 Binding of inhibitor, mitochondrial complex III leads to Increase, Mitochondrial complex III antagonism
1945 Binding of inhibitor, mitochondrial complex IV leads to Mitochondrial Complex IV inhibition
1946 Binding of inhibitor, mitochondrial complex V leads to Mitochondrial Complex V inhibition
1947 TR Antagnoism leads to Hippocampal gene expression, Altered
1948 TR Antagnoism leads to Cognitive Function, Decreased
1949 CBS inhibition leads to Homocysteine increases
1951 Methionine synthase leads to Homocysteine increases
1950 MTHFR inhibition leads to Homocysteine increases
1952 betaine-homocysteine methyltransferase inhibition leads to Homocysteine increases
1953 Homocysteine increases leads to plasma homocysteine increases
1959 Homocysteine increases leads to Plasma HCY level
1954 plasma homocysteine increases leads to brain Homocysteine level increases
1955 brain Homocysteine level increases leads to Neuronal dysfunctions induction
1960 Plasma HCY level leads to dysfunction of microcirculation
1961 dysfunction of microcirculation leads to anterior-posterior axis development
2512 dysfunction of microcirculation leads to Increased inflammatory immune responses
2415 Frustrated phagocytosis leads to Increased proinflammatory mediators
2416 Frustrated phagocytosis leads to Increased, Reactive oxygen species
1962 Frustrated phagocytosis leads to Release, Cytokine
2608 Increased, DNA damage and mutation leads to Inadequate DNA repair
2417 Increased, DNA damage and mutation leads to Genomic instability
2728 Increased, DNA damage and mutation leads to Increase chromosomal aberrations
1966 Increased, DNA damage and mutation leads to Increase, Cell Proliferation
1968 Substance - LS interaction leads to Inhibition of LS function.
2370 Inhibition of LS function. leads to Decreased lung function
1969 Inhibition of LS function. leads to Alveolar collapse
2255 Inhibition of LS function. leads to Loss of alveolar capillary membrane integrity
2256 Inhibition of LS function. leads to Reduced tidal volume
2371 Alveolar collapse leads to Decreased lung function
1970 Alveolar collapse leads to Alveolar reopening
1974 Alveolar collapse leads to Reduced tidal volume
2284 Alveolar collapse leads to Loss of alveolar capillary membrane integrity
2285 Alveolar collapse leads to Impaired lung function
2173 Alveolar reopening leads to Loss of alveolar capillary membrane integrity
1971 Alveolar reopening leads to Loss of barrier function
1972 Loss of barrier function leads to Blood extravasation into the lungs
1973 Blood extravasation into the lungs leads to Acute inhalation toxicity
2367 Reduced tidal volume leads to Decreased lung function
1975 Reduced tidal volume leads to Impaired oxygenation of the blood
2257 Reduced tidal volume leads to Impaired lung function
1976 Impaired oxygenation of the blood leads to Acute inhalation toxicity
2562 Disruption, Progenitor cells of second heart field leads to Reduced neural crest cell migration
2832 Energy Deposition leads to Tissue resident cell activation
2837 Energy Deposition leads to Increase, Neural Remodeling
2838 Energy Deposition leads to Impairment, Learning and memory
2847 Energy Deposition leads to Altered Bone Cell Homeostasis
2848 Energy Deposition leads to Bone Remodeling
2849 Energy Deposition leads to Bone Loss
2604 Energy Deposition leads to Microcephaly
2616 Energy Deposition leads to Increase in RONS
1977 Energy Deposition leads to Increase, DNA strand breaks
1981 Energy Deposition leads to Increase, Mutations
1982 Energy Deposition leads to Increase, Chromosomal aberrations
1983 Energy Deposition leads to Increase, lung cancer
2769 Energy Deposition leads to Oxidative Stress
2770 Energy Deposition leads to Vascular remodeling
2779 Energy Deposition leads to Altered, Nitric Oxide Levels
2780 Energy Deposition leads to Increase, Endothelial Dysfunction
2785 Energy Deposition leads to Occurrence, Vascular Remodeling
2548 Energy Deposition leads to Increased, Reactive oxygen species
2552 Energy Deposition leads to Increase, DNA Damage
2809 Energy Deposition leads to Modified Proteins
2557 Energy Deposition leads to Increase, ROS production
2813 Energy Deposition leads to Increase, Oxidative DNA damage
2814 Energy Deposition leads to Increase, Cell Proliferation
2815 Energy Deposition leads to Cataracts
2129 decrease, transcription of genes by AR leads to AGD, decreased
2126 Decrease, testosterone levels leads to Decrease, DHT level
2131 Decrease, testosterone levels leads to Decrease, AR activation
1986 Antagonism,LH receptor leads to Reduction, Progesterone synthesis
1987 Reduction, Progesterone synthesis leads to Reduction, Plasma progesterone concentration
1988 Reduction, Plasma progesterone concentration leads to Reduction, progesterone uptake, decresed maturation
1989 Reduction, progesterone uptake, decresed maturation leads to Impaired ovulation
1990 Impaired ovulation leads to Decrease of egg production and cummulative fecundity
2389 Decrease of egg production and cummulative fecundity leads to Decreased, Population size
1991 Decrease of egg production and cummulative fecundity leads to Decline, Population trajectory
1993 Increase, DNMT expression leads to Increase, hypermethylation of the promotor region of GnRHR
1994 Increase, hypermethylation of the promotor region of GnRHR leads to Decease, expression of GnRHR
1995 Decease, expression of GnRHR leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
2000 Impaired IL-1R1 signaling leads to Suppression of T cell activation
2002 Impaired IL-1R1 signaling leads to Inhibition, Nuclear factor kappa B (NF-kB)
2927 Suppression of T cell activation leads to Impaired IL-1R1 signaling
2928 Suppression of T cell activation leads to Impairment, T-cell dependent antibody response
2001 Suppression of T cell activation leads to Inhibition, Nuclear factor kappa B (NF-kB)
2004 Suppression of T cell activation leads to Impairment of TDAR
2006 Cardiovascular dysregulation leads to Respiratory distress/arrest
2034 test leads to Unknown, MIE
2037 test leads to N/A, Unknown
2012 Impaired coordination and movement leads to Increased Mortality
2015 Impaired coordination and movement leads to Decrease, Population growth rate
2017 Stimulation of TLR7/8 leads to Increase of IL-23
2018 Increase of IL-23 leads to Th17 cell migration and inflammation induction
2019 Th17 cell migration and inflammation induction leads to Skin disease
2020 Binding to estrogen receptor (ER)-α leads to Induction of GATA3 expression
2021 Induction of GATA3 expression leads to Increase of Th2 cells producing IL-4
2022 Increase of Th2 cells producing IL-4 leads to Increase of autoantibody production
2023 Increase of autoantibody production leads to Exacerbation of SLE
2024 Inhibition of JAK3 leads to STAT5 inhibition
2025 STAT5 inhibition leads to Suppression of STAT5 binding to cytokine gene promoters
2026 Suppression of STAT5 binding to cytokine gene promoters leads to Suppression of IL-4 production
2027 Suppression of IL-4 production leads to Impairment, TDAR
2028 Inhibition, trypsin leads to Increased monitor peptide
2029 Increased monitor peptide leads to Increased blood CCK level
2030 Increased blood CCK level leads to Increased acinar cell exocrine secretion
2031 Increased acinar cell exocrine secretion leads to Acinar cell proliferation
2032 Acinar cell proliferation leads to Acinar cell tumors
2052 SARS-CoV-2 cell entry leads to Increased proinflammatory mediators
2310 SARS-CoV-2 cell entry leads to SARS-CoV-2 production
2314 SARS-CoV-2 cell entry leads to Increased viral transcription and replication
2361 SARS-CoV-2 cell entry leads to Sustentacular cells, decrease
2496 SARS-CoV-2 cell entry leads to IFN-I response, antagonized
2510 SARS-CoV-2 cell entry leads to Endothelial cell dysfunction
2302 SARS-CoV-2 cell entry leads to TLR Activation/Dysregulation
2311 Binding to ACE2 leads to ACE2 dysregulation
2056 Binding to ACE2 leads to SARS-CoV-2 cell entry
2312 Binding to ACE2 leads to Downregulation of ACE2
2452 Binding to ACE2 leads to Endothelial cell dysfunction
2522 Binding to ACE2 leads to ADAM17 induction
2286 Binding to ACE2 leads to Neuroinflammation
2294 Binding to ACE2 leads to Induced, Angiotensin (Ang) II accumulation
2297 Binding to ACE2 leads to Increased AngII
2299 Binding to ACE2 leads to ACE2 enzymatic inhibition
2065 ACE2 enzymatic inhibition leads to Increased AngII
2321 ACE2 enzymatic inhibition leads to Induced, Angiotensin (Ang) II accumulation
2434 ACE2 enzymatic inhibition leads to Increase plasma Ang II
2322 Induced, Angiotensin (Ang) II accumulation leads to Increased Ang II type 1 receptor (AT1R)
2520 Induced, Angiotensin (Ang) II accumulation leads to Hyperactivation of ACE/Ang-II/AT1R axis
2295 Induced, Angiotensin (Ang) II accumulation leads to Impaired gustatory nerve
2067 Increase plasma Ang II leads to Increase,collagen synthesis
2138 Increase plasma Ang II leads to Accumulation, Collagen
2435 Increase plasma Ang II leads to Increased Ang II type 1 receptor (AT1R)
2068 Increase,collagen synthesis leads to Induction lung fibrosis
2064 Increase, the risk of acute respiratory failure leads to Decreased mortality
2135 Increase, the risk of acute respiratory failure leads to Increased Mortality
2062 Increased inflammatory immune responses leads to Increase, the risk of acute respiratory failure
2513 Increased inflammatory immune responses leads to Heart attack
2317 Increased AngII leads to Sodium inhibition, Sweet enhancement
2066 Increased AngII leads to Increase plasma Ang II
2327 Increased AngII leads to Increased Ang II type 1 receptor (AT1R)
2593 Increased AngII leads to Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R)
2298 Increased AngII leads to Impaired gustatory nerve
2300 Increased AngII leads to Increased proinflammatory mediators
2069 Chronic ROS leads to Porcupine-induced Wnt secretion and Wnt signaling activation
2070 Porcupine-induced Wnt secretion and Wnt signaling activation leads to beta-catenin activation
2071 beta-catenin activation leads to Epithelial-mesenchymal transition
2076 Decreased, 11KT leads to Impaired, Spermatogenesis
2165 Decreased, 11KT leads to Decrease, Fertility
2166 Decreased, 11KT leads to Decreased spermatogenesis
2164 Impaired, Spermatogenesis leads to Decrease, Fertility
2937 Impaired, Spermatogenesis leads to Decreased, Viable Offspring
2692 Impaired, Spermatogenesis leads to Viable offspring, decreased
2274 Impaired, Spermatogenesis leads to impaired, Fertility
2078 Increase, Cripto-1 expression leads to Inhibition, Activin signaling
2082 Increase, Cripto-1 expression leads to Inhibition, Fin regeneration
2079 Inhibition, Activin signaling leads to Inhibition, Fin regeneration
2080 Inhibition, Fin regeneration leads to Reduced, Swimming performance
2084 cell injury leads to Increase, Regenerative cell proliferation (urothelial cells)
2087 Increase, Formation of DNA photoproducts leads to Increase, DNA DSB
2088 Increase, DNA DSB leads to Increase, Apoptosis
2109 Increase, DNA DSB leads to Increase, Casp transcription
2090 Increase, Protein oxidation leads to Increase, Abnormal osmoregulation
2223 Increase, Protein oxidation leads to Increase, Cell death
2091 Increase, Abnormal osmoregulation leads to Increase, Body fluid overload
2181 Increase, Abnormal osmoregulation leads to Increase, Tissue/organ damage
2092 Increase, Body fluid overload leads to Increase, Mortality
2347 Decrease, MMP leads to Increase, Programmed cell death
2094 Decrease, MMP leads to Decrease, OXPHOS
2637 Decrease, MMP leads to Increase, Mt Dysfunction
2096 Decrease, ATP pool leads to Increase, Mortality
2120 Decrease, ATP pool leads to Increase, Oocyte apoptosis
2121 Decrease, ATP pool leads to Increase, Necrosis
2179 Decrease, ATP pool leads to Decrease, ATPase activity
2204 Decrease, ATP pool leads to Decrease, Cell proliferation
2209 Decrease, ATP pool leads to Decrease, Oogenesis
2214 Decrease, ATP pool leads to Increase, Cell death
2216 Decrease, ATP pool leads to Increase, Fatty acid β-oxidation
2768 Decrease, ATP pool leads to Cell injury/death
2786 Decrease, ATP pool leads to Decreased Na/K ATPase activity
2098 Decrease, Neutral lipids leads to Decrease, ATP pool
2102 Decrease, Global DNA methylation leads to Increase, Casp transcription
2110 Decrease, Global DNA methylation leads to Decrease, Heritable DNA methylation (F3)
2103 Increase, Casp transcription leads to Increase, Oocyte apoptosis
2105 Increase, Casp transcription leads to Increase, Ovarian somatic cell apoptosis
2104 Increase, Oocyte apoptosis leads to Decrease, Oogenesis
2386 Increase, Oocyte apoptosis leads to impaired, Fertility
2400 Increase, Oocyte apoptosis leads to Decrease of egg production and cummulative fecundity
2106 Increase, Ovarian somatic cell apoptosis leads to Increase, Ovarian follicle breakdown
2560 Increase, Ovarian follicle breakdown leads to Decrease, Fecundity
2107 Increase, Ovarian follicle breakdown leads to Decrease, Oogenesis
2111 Decrease, Heritable DNA methylation (F3) leads to Increase, Casp transcription (F3)
2112 Increase, Casp transcription (F3) leads to Increase, Oocyte apoptosis (F3)
2116 Increase, Casp transcription (F3) leads to Increase, Ovarian somatic cell apoptosis (F3)
2113 Increase, Oocyte apoptosis (F3) leads to Decrease, Oogenesis (F3)
2115 Decrease, Fecundity (F3) leads to Decrease, Population growth rate
2114 Decrease, Oogenesis (F3) leads to Decrease, Fecundity (F3)
2117 Increase, Ovarian somatic cell apoptosis (F3) leads to Increase, Ovarian follicle breakdown (F3)
2118 Increase, Ovarian follicle breakdown (F3) leads to Decrease, Oogenesis (F3)
2119 Increase, Mitochondrial ATP synthase antagonism leads to Decrease, OXPHOS
2229 Increase, Mitochondrial ATP synthase antagonism leads to Decrease, ATP pool
2136 Downregulation of ACE2 leads to Increase plasma Ang II
2137 Downregulation of ACE2 leads to Increased AngII
2517 Downregulation of ACE2 leads to Ang (1-7) levels reduced
2141 Status epilepticus leads to Overactivation, NMDARs
2782 Status epilepticus leads to Increased, glutamate
2783 Status epilepticus leads to Increased, Intracellular Calcium overload
2145 Reduction, E2 Synthesis by the undifferentiated gonad leads to Increased, Differentiation to Testis
2146 Increased, Differentiation to Testis leads to Increased, Male Biased Sex Ratio
2147 Increased, Male Biased Sex Ratio leads to Decrease, Population growth rate
2148 TLR4 activation leads to Activation, JNK
2155 TLR4 activation leads to Activation, TGF-beta pathway
2251 TLR4 activation leads to AP-1 activation
2157 AP-1 activation leads to TGFbeta expression
2151 Pin-1 activation leads to TGFbeta expression
2152 TGFbeta expression leads to Activation, TGF-beta pathway
2158 11β-hydroxylase inhibition leads to Decreased, 11KT
2275 11β-hydroxylase inhibition leads to Cortisol and 11β-(OH) testosterone decreased
2620 Decreased spermatogenesis leads to Decrease, Fecundity
2623 Decreased spermatogenesis leads to Decrease, Reproduction
2624 Decreased spermatogenesis leads to Decrease, Population growth rate
2388 Decreased spermatogenesis leads to Decrease of egg production and cummulative fecundity
2161 Decreased spermatogenesis leads to impaired, Fertility
2162 Inhibition of 11β-HSD leads to Decreased, 11KT
2170 Inhibition, Chitinase leads to Decrease, Digestion of old cuticle
2172 Inhibition, Chitobiase leads to Decrease, Digestion of old cuticle
2344 Decrease, ATP synthase activity leads to Decrease, Leaf development
2176 Decrease, ATP synthase activity leads to Decrease, ATP pool
2178 Increase, Tissue/organ damage leads to Decrease, Growth
2180 Decrease, ATPase activity leads to Increase, Abnormal osmoregulation
2183 Increase, Complex III dysfunction leads to Increase, Cyt c release
2186 Increase, Complex III dysfunction leads to Increase, ROS production
2184 Increase, Cyt c release leads to Increase, Apoptosis
3050 Increase, Cyt c release leads to Caspase activation
2189 Increase, Complex I dysfunction leads to Increase, ROS production
2192 Reactive Metabolite leads to Mitochondrial dysfunction
2194 Reactive Metabolite leads to Immune cell activation
2643 ER stress leads to Increase, Apoptosis
2200 ER stress leads to Apoptotic cell death
2932 Mitochondrial dysfunction leads to Impaired insulin signaling
2193 Mitochondrial dysfunction leads to Apoptotic cell death
2195 Mitochondrial dysfunction leads to ER stress
2499 Mitochondrial dysfunction leads to Oxidative Stress
3043 Mitochondrial dysfunction leads to Proteasomal dysfunction
2198 Apoptotic cell death leads to Increase in inflammation
2196 Immune cell activation leads to IFNγ signaling
2197 IFNγ signaling leads to Increase in inflammation
2405 Decrease, Cell proliferation leads to Decreased, Eye size
2205 Decrease, Cell proliferation leads to Decrease, Growth
2724 Decrease, Cell proliferation leads to Decrease, outgrowth
2207 Decrease, Lipid storage leads to Decrease, FAO
2218 Decrease, Lipid storage leads to Decrease, Growth
2208 Decrease, FAO leads to Decrease, ATP pool
2842 Increase, Cell death leads to Altered Bone Cell Homeostasis
2863 Increase, Cell death leads to Hippocampal Physiology, Altered
2706 Increase, Cell death leads to Parkinsonian motor deficits
2718 Increase, Cell death leads to Neuroinflammation
2467 Increase, Cell death leads to Altered, inner ear development
2215 Increase, Cell death leads to Decrease, Growth
2489 Increase, Cell death leads to Disruption of the intestinal barrier
2760 Increase, Cell death leads to Increased proinflammatory mediators
2220 Increase, Oxygen consumption leads to Increase, ROS production
2226 Increase, Global methylation leads to Increase, Apoptosis
2241 Increased, Thyroxine (T4) in serum leads to Altered, Amphibian metamorphosis
2242 Increased, Thyroxine (T4) in serum leads to Altered, TH-dependent gene expression
2244 Altered, TH-dependent gene expression leads to Altered, Amphibian metamorphosis
2249 Displacement, Serum thyroxine (T4) from carrier protein leads to Increased, Free serum thyroxine (T4)
2250 Binding, Thyroid binding globulin in serum leads to Displacement, Serum thyroxine (T4) from carrier protein
2267 Decrease, ACAD leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
2276 Cortisol and 11β-(OH) testosterone decreased leads to Decreased plasma Cortisol level
2277 Cortisol and 11β-(OH) testosterone decreased leads to Decreased, 11KT
2278 Decreased plasma Cortisol level leads to decreased oocyte maturation
2293 decreased oocyte maturation leads to impaired, Fertility
2429 TLR9 activation leads to MyD88 activation
2433 TLR9 activation leads to inflammasome activity, increased
2313 Coagulation leads to Oxidative Stress
2360 Coagulation leads to Diminished Protective Response to ROS
2290 Coagulation leads to Thrombosis and DIC
2351 SARS-CoV-2 production leads to TLR Activation/Dysregulation
2358 SARS-CoV-2 production leads to Diminished Protective Response to ROS
2488 SARS-CoV-2 production leads to Increase, Cell death
2498 SARS-CoV-2 production leads to Viral infection, proliferated
2545 SARS-CoV-2 production leads to Sustentacular cells, decrease
2546 SARS-CoV-2 production leads to Disruption of the intestinal barrier
2291 SARS-CoV-2 production leads to Oxidative Stress
2303 TLR Activation/Dysregulation leads to Increased proinflammatory mediators
2296 Impaired gustatory nerve leads to taste impairment
2304 Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) leads to Increase, ROS production
2319 Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) leads to Increased, Reactive oxygen species
2323 Increased Ang II type 1 receptor (AT1R) leads to Increased, Reactive oxygen species
2326 Hyperactivation of ACE/Ang-II/AT1R axis leads to Increased AngII
2521 Hyperactivation of ACE/Ang-II/AT1R axis leads to Heart failure
2831 ACE2 dysregulation leads to (Micro)vascular dysfunction
2493 ACE2 dysregulation leads to Recruitment of inflammatory cells
2532 ACE2 dysregulation leads to Gut dysbiosis
2329 Increased Sodium-sensitive hypertension leads to Chronic kidney disease
2318 Sodium inhibition, Sweet enhancement leads to Impaired gustatory nerve
2458 Platelet-neutrophil interactions, Increased leads to Thromboinflammation, Increased
2315 Increased viral transcription and replication leads to Increased proinflammatory mediators
2316 Increased viral transcription and replication leads to TLR Activation/Dysregulation
2330 Excitation of intracellular water leads to Increase in RONS
2332 D1 protein deactivation leads to Decrease, Photosystem II efficiency
2333 Decrease, Photosystem II efficiency leads to Decrease, Photosynthesis
2336 Decrease, Reproduction leads to Decrease, Population growth rate
2556 Decrease, Reproduction leads to Decreased, Population trajectory
2339 Increase, Programmed cell death leads to Decrease, Leaf development
2553 Increase, Programmed cell death leads to Decrease, Reproduction
2340 Increase, OEC damage leads to Decrease, Photosystem II efficiency
2352 Hypofibrinolysis leads to Bradykinin, activated
2356 Hypofibrinolysis leads to Increased proinflammatory mediators
2353 Bradykinin, activated leads to Increased proinflammatory mediators
2355 Bradykinin, activated leads to Hypofibrinolysis
2357 Bradykinin, activated leads to Hyperinflammation
2762 Hyperinflammation leads to Increase, the risk of acute respiratory failure
2359 Diminished Protective Response to ROS leads to Coagulation
2413 Diminished Protective Response to ROS leads to inflammasome activity, increased
2362 Sustentacular cells, decrease leads to olfacotry neurons, decrease
2365 Sustentacular cells, decrease leads to anosmia
2363 olfacotry neurons, decrease leads to Olfactory epithelium degeneration
2366 olfacotry neurons, decrease leads to anosmia
2364 Olfactory epithelium degeneration leads to anosmia
2374 Altered, retinal layer structure leads to Altered, Visual function
2377 Decreased, Eye size leads to Altered, Visual function
2406 Decreased, Eye size leads to Increased Mortality
2398 Bulky DNA adducts, increase leads to Inadequate DNA repair
2399 Bulky DNA adducts, increase leads to Increase, Mutations
2401 ALDH1A (RALDH), inhibition leads to Decreased, atRA concentration
2561 Decreased, atRA concentration leads to Disruption, Progenitor cells of second heart field
2477 Decreased, atRA concentration leads to Oocyte meiosis, disrupted
2481 Oocyte meiosis, disrupted leads to Ovarian follicle pool, reduced
2480 Ovarian follicle pool, reduced leads to Decreased fertility, Reduced number of oocytes ovulated
2487 Ovarian follicle pool, reduced leads to impaired, Fertility
2525 Ovarian follicle pool, reduced leads to irregularities, ovarian cycle
2402 Inhibition of Fyna leads to Inhibition of Plxna2
2403 Inhibition of Plxna2 leads to Overexpression of rasl11b
2404 Overexpression of rasl11b leads to Decrease, Cell proliferation
2527 increased atRA concentration leads to premature meiosis, male germ cells
2408 abnormal, placental labyrinth vasculature morphology leads to increase, placental insufficiency
2409 increase, placental insufficiency leads to increase, Preeclampsia
2414 inflammasome activity, increased leads to Hyperinflammation
2418 Genomic instability leads to Increase, Cell Proliferation
2973 Genomic instability leads to endometrioid adenocarcinoma Type I
2430 MyD88 activation leads to Increased activation, Nuclear factor kappa B (NF-kB)
2497 IFN-I response, antagonized leads to SARS-CoV-2 production
2436 Repression of Gbx2 expression leads to foxi1 expression, increased
2437 foxi1 expression, increased leads to six1b expression, increased
2438 six1b expression, increased leads to eya1 expression, inhibited
2439 eya1 expression, inhibited leads to Increase, Cell death
2440 CFTR Function, Decreased leads to ASL Height, Decreased
2441 ASL Height, Decreased leads to CBF, Decreased
2444 ASL Height, Decreased leads to Mucus Viscosity, Increased
2442 CBF, Decreased leads to MCC, Decreased
2443 MCC, Decreased leads to Decreased lung function
2445 Mucus Viscosity, Increased leads to CBF, Decreased
2446 Mucus Viscosity, Increased leads to MCC, Decreased
2447 FOXJ1 Protein, Decreased leads to Motile Cilia Number/Length, Decreased
2448 Motile Cilia Number/Length, Decreased leads to CBF, Decreased
2453 Endothelial cell dysfunction leads to Release, Cytokine
2511 Endothelial cell dysfunction leads to dysfunction of microcirculation
2456 Platelet activation, Increased leads to Platelet-neutrophil interactions, Increased
2457 Neutrophil activation, Increased leads to Platelet-neutrophil interactions, Increased
2641 Altered expression of NRF2 pathway-dependent genes leads to ER stress
2642 Altered expression of NRF2 pathway-dependent genes leads to Increased, Oxidative Stress
2855 Increased，Cardiac dysfunction leads to Increased Mortality
2982 increased，Vascular endothelial dysfunction leads to Angiogenesis disfunction
3019 increased，Vascular endothelial dysfunction leads to Impaired Platelet Aggregation
3027 increased，Vascular endothelial dysfunction leads to Vascular barrier disruption
3031 increased，Vascular endothelial dysfunction leads to Angiogenesis dysfunction
2468 Altered, inner ear development leads to Reduced, Hearing
2490 Disruption of the intestinal barrier leads to Recruitment of inflammatory cells
2494 Disruption of the intestinal barrier leads to GI disorders
2495 Disruption of the intestinal barrier leads to Hyperinflammation
2518 Ang (1-7) levels reduced leads to Degradation of Ang-II reduced
2519 Degradation of Ang-II reduced leads to Induced, Angiotensin (Ang) II accumulation
2523 ADAM17 induction leads to ACE2 increased shedding
2524 ACE2 increased shedding leads to Ang (1-7) levels reduced
2526 Increases in cellular ROS leads to Porcupine-induced Wnt secretion and Wnt signaling activation
2503 Accumulation, Toxic Tau oligomers leads to Impaired axonial transport
2507 Accumulation, Toxic Tau oligomers leads to Neuroinflammation
2504 Dysfunctional synapses leads to Neuronal network function, Decreased
2808 Dysfunctional synapses leads to Impairment, Learning and memory
2676 Dysfunctional autophagy leads to Emphysema
2502 Dysfunctional autophagy leads to Accumulation, Toxic Tau oligomers
2515 Altered mechanotransduction properties of pericytes leads to Pericyte dysfunction
2516 Pericyte dysfunction leads to Endothelial cell dysfunction
2509 Upregulation of ACE2 leads to SARS-CoV-2 cell entry
2529 Decrease, GLUT4 leads to Decrease, Glucose uptake
2528 Increase, TNF leads to Decrease, GLUT4
2530 Decrease, Glucose uptake leads to Abnormal, Glucose homeostasis
2531 Abnormal, Glucose homeostasis leads to GDM
2533 Gut dysbiosis leads to Disruption of the intestinal barrier
2544 Gut dysbiosis leads to Recruitment of inflammatory cells
2534 Binding to hERG channel leads to Direct hERG channel blockage
2535 hERG channel biogenesis interference leads to Direct hERG channel blockage
2536 hERG channel biogenesis interference leads to Induction of hERG trafficking defects
2537 Direct hERG channel blockage leads to Inhibition of Ikr
2538 Induction of hERG trafficking defects leads to Inhibition of Ikr
2539 Inhibition of Ikr leads to Prolongation of Action Potential
2540 Prolongation of Action Potential leads to Prolongation of QT interval
2853 Prolongation of QT interval leads to Occurrence, cardiac arrhythmia
2541 Prolongation of QT interval leads to Torsades de Pointes
2852 Torsades de Pointes leads to Increased Mortality
2542 Torsades de Pointes leads to Sudden cardiac death
2555 Increase, Pollen abnormal leads to Decrease, Reproduction
2567 Increase, Mt Dysfunction leads to Increase, Cytotoxicity (renal tubular cell)
2638 Increase, Mt Dysfunction leads to Altered expression of NRF2 pathway-dependent genes
2639 Increase, Mt Dysfunction leads to Inhibition, Nuclear factor kappa B (NF-kB)
2640 Increase, Mt Dysfunction leads to Increase, Apoptosis
2964 Increase, Mt Dysfunction leads to Increased, Reactive oxygen species
3017 Increase, Mt Dysfunction leads to Increase, Vascular disrupting effects
3026 Increase, Mt Dysfunction leads to increased，Vascular endothelial dysfunction
2566 Increase, Oxidative Stress leads to Increase, Mt Dysfunction
2897 Increase, Oxidative Stress leads to TH synthesis, Decreased
2980 Increase, Oxidative Stress leads to Activation, inflammation pathway
2993 Increase, Oxidative Stress leads to Abnormal expression of NO
2999 Increase, Oxidative Stress leads to Activated ANG/Tie2 pathway
3000 Increase, Oxidative Stress leads to Activation, Dll4-Notch pathway
3001 Increase, Oxidative Stress leads to Activated BMP/TGF-beta pathway
3002 Increase, Oxidative Stress leads to Activated Wnt/Frizzled pathway
3003 Increase, Oxidative Stress leads to Uncoupling, eNOS
3004 Increase, Oxidative Stress leads to Activated AKT/ERK/PI3K pathway
3005 Increase, Oxidative Stress leads to Inhibition VEGF/VEGFR pathway
3033 Increase, Oxidative Stress leads to Increase, Apoptosis
2579 tumor growth leads to N/A, Breast Cancer
2582 Increased, Steroidogenic acute regulatory protein (StAR) leads to Increased, estrogens
2583 Increased, estrogens leads to Increased, circulating estrogen levels
2600 Activation of TP53 leads to Increase, Apoptosis
2601 Activation of TP53 leads to Altered differentiation
2606 Activation of TP53 leads to Premature differentiation
2615 Altered kinetics of sodium channel leads to Altered, Action Potential
2625 Altered kinetics of sodium channel leads to Disruption in action potential generation
2607 Premature differentiation leads to Microcephaly
2610 Increase,miRNA levels leads to Decrease,SIRT1(sirtuin 1) levels
2611 Decrease,SIRT1(sirtuin 1) levels leads to Increased activation, Nuclear factor kappa B (NF-kB)
2626 Agonism, Estrogen Receptor alpha leads to Increased, Kisspeptin signalling
2628 Agonism, Estrogen Receptor alpha leads to Decreased, Gonadotropins
2627 Increased, Kisspeptin signalling leads to Decreased, Gonadotropins
2629 Decreased, Gonadotropins leads to Decreased , Androgen and Progestin
2630 Decreased , Androgen and Progestin leads to Decreased, Maturation Inducing Steroids Surge by Granulosa cells
2631 Decreased, Maturation Inducing Steroids Surge by Granulosa cells leads to Impaired, Oocyte maturation and ovulation
2632 Impaired, Oocyte maturation and ovulation leads to Increased, Oocyte Atresia
2633 Increased, Oocyte Atresia leads to Impaired, Reproduction
2862 Microglia activation leads to Neuroinflammation
2661 Secondary genotoxicity leads to Increased, DNA damage and mutation
2667 Non-coding RNA expression，alteration leads to Activation, inflammation pathway
2668 Non-coding RNA expression，alteration leads to Oxidative Stress
2669 Non-coding RNA expression，alteration leads to Epithelial-mesenchymal transition
2670 Non-coding RNA expression，alteration leads to Fibroblast proliferation and differentiation
2671 Non-coding RNA expression，alteration leads to Apoptosis
2672 Non-coding RNA expression，alteration leads to Dysfunctional autophagy
2673 Activation, inflammation pathway leads to Pulmonary inflammation
2981 Activation, inflammation pathway leads to increased，Vascular endothelial dysfunction
3006 Activation, inflammation pathway leads to Endothelial cell death
3007 Activation, inflammation pathway leads to Decreased endothelial cell proliferation
3008 Activation, inflammation pathway leads to Decrease, ATP production
3009 Activation, inflammation pathway leads to Increase, Vascular disrupting effects
2679 Pulmonary inflammation leads to Chronic obstructive pulmonary disease
2680 Emphysema leads to Chronic obstructive pulmonary disease
2678 Fibroblast proliferation and differentiation leads to Airway remodeling
2681 Airway remodeling leads to Chronic obstructive pulmonary disease
2711 Endoplasmic reticulum stress leads to Unfolded Protein Response
2905 Insulin resistance leads to Metabolically unhealthy Obesity
2935 Insulin resistance leads to Metabolic syndrome
2685 Decrease, sox9 expression leads to Smaller and morphologically distorted facial cartilage structures
2691 Decrease, sox9 expression leads to Altered, Cardiovascular development/function
2684 Increase, slincR expression leads to Decrease, sox9 expression
2690 Increase, slincR expression leads to Smaller and morphologically distorted facial cartilage structures
2727 Increase, slincR expression leads to Altered, Cardiovascular development/function
2694 Inhibition CerS leads to Reduced complex sphingolipids
2697 Inhibition CerS leads to Increased S1-P
2695 Reduced complex sphingolipids leads to Affected folate transporter
2696 Affected folate transporter leads to decrease folate
2700 decrease folate leads to Neural tube defects
2894 Antagonism Smoothened leads to OFC
2720 Antagonism Smoothened leads to Decrease, GLI1/2 translocation
2734 Antagonism Smoothened leads to Decrease, SMO relocation
2721 Decrease, GLI1/2 translocation leads to Decrease, GLI1/2 target gene expression
2719 PARP1 leads to N/A, Mitochondrial dysfunction 1
2693 Viable offspring, decreased leads to Decrease, Population growth rate
2698 Increased S1-P leads to Histone deacetylase inhibition
2701 Activation, mGLUr leads to Increased, Intracellular Calcium overload
2703 Activation, mGLUr leads to Activation, IP3R
2702 Activation, IP3R leads to Increased, Intracellular Calcium overload
3037 Activation, IP3R leads to Increased, glutamate
2705 Activation, calpain leads to Increase, Cell death
2707 Inhibition, GABAAr leads to Increase, Cell membrane depolarization
2882 Decrease, GLI1/2 target gene expression leads to Apoptosis
2722 Decrease, GLI1/2 target gene expression leads to Decrease, Cell proliferation
2723 Decrease, GLI1/2 target gene expression leads to Increase, Apoptosis
2731 Decrease, GLI1/2 target gene expression leads to Decrease, SHH second messenger production
2805 Decrease, GLI1/2 target gene expression leads to Decrease, outgrowth
2726 Decrease, outgrowth leads to OFC
2957 Decrease, SHH second messenger production leads to Apoptosis
2732 Decrease, SHH second messenger production leads to Decrease, Cell proliferation
2733 Decrease, SHH second messenger production leads to Increase, Apoptosis
2735 Decrease, SMO relocation leads to Decrease, GLI1/2 translocation
2736 Increase, Alcohol dehydrogenase leads to Increased, Estrogen receptor (ER) activity
2738 Increase, Vitellogenin mRNA leads to Delay, Ovarian maturation
2739 Delay, Ovarian maturation leads to Increase, Body volume of female adults
2740 Delay, Ovarian maturation leads to Increase, sex ratio (F/M)
2741 Increase, Body volume of female adults leads to Increase, developmental abnormalities
2742 Increase, sex ratio (F/M) leads to Increase, developmental abnormalities
2743 Increase, developmental abnormalities leads to Increase, Mortality
2744 Decrease, Tyrosine leads to Decrease, dopa decarboxylase
2745 Decrease, dopa decarboxylase leads to Increase, Defects in tanning of new cuticle
2746 Increase, Defects in tanning of new cuticle leads to Increase, impairment of cuticle sclerotization
2747 Increase, Defects in tanning of new cuticle leads to Increase, pigmentation
2748 Increase, impairment of cuticle sclerotization leads to Increase, Incomplete ecdysis
2749 Increase, pigmentation leads to Increase, Incomplete ecdysis
2752 Decrease, 20-hydroxyecdysone leads to Decrease, knickkopf gene
2753 Decrease, knickkopf gene leads to Decrease, Chitin laminar organization
2754 Decrease, knickkopf gene leads to Decrease, Prevent chitin degradation by chitinases
2755 Decrease, Chitin laminar organization leads to Weak, Procuticle protection
2756 Decrease, Prevent chitin degradation by chitinases leads to Weak, Procuticle protection
2757 Weak, Procuticle protection leads to Decrease, New cuticle secretion
2758 Decrease, New cuticle secretion leads to Increase, Incomplete ecdysis
2764 Increase, Cytosolic Ca leads to Increase, Cell death
2766 Increase, Cytosolic Ca leads to Cell injury/death
2840 Altered Signaling leads to Increase, Neural Remodeling
2843 Altered Signaling leads to Altered Bone Cell Homeostasis
2773 Altered Signaling leads to Altered, Nitric Oxide Levels
2775 Altered Signaling leads to Increase, Endothelial Dysfunction
2789 Altered, Nitric Oxide Levels leads to Increase, Endothelial Dysfunction
2778 Increase, Endothelial Dysfunction leads to Vascular remodeling
2784 Increase, Endothelial Dysfunction leads to Occurrence, Vascular Remodeling
2794 Increase, Glycolysis leads to Decrease, Glucose pool
2795 Decrease, Glucose pool leads to Decrease, Cell proliferation
2797 Increase, Mitochondrial swelling leads to Cell injury/death
2799 methemocyanin formation (decrease overall oxygen binding capacity) leads to Decrease overall oxygen binding capacity (methemocyanin formation)
2800 methemocyanin formation (decrease overall oxygen binding capacity) leads to Hemocyanin Bohr effect decrease
2803 Decrease overall oxygen binding capacity (methemocyanin formation) leads to Increase, hemocyanin mRNA
2801 Hemocyanin Bohr effect decrease leads to behavioral change leading to possible reduced feeding opportunity
2802 behavioral change leading to possible reduced feeding opportunity leads to Decrease, Growth
2807 Loss of drebrin leads to Dysfunctional synapses
2816 Modified Proteins leads to Cataracts
2844 Altered Bone Cell Homeostasis leads to Bone Remodeling
2845 Bone Remodeling leads to Bone Loss
2835 Increase, Pro-Inflammatory Mediators leads to Increase, Neural Remodeling
2839 Increase, Pro-Inflammatory Mediators leads to Impairment, Learning and memory
2836 Increase, Neural Remodeling leads to Impairment, Learning and memory
2850 hERG channel blockade leads to Inhibition of rapid delayed rectifying potassium current
2851 Inhibition of rapid delayed rectifying potassium current leads to Prolongation of Action Potential
2858 Increase, goblet cell number leads to Increase, Mucin production
2866 SDH, inhibited leads to Superoxide generation, increased
2895 SDH, inhibited leads to Increase, Oxidative Stress
2896 Superoxide generation, increased leads to Increase, Oxidative Stress
2867 decreased, IQ leads to increased, Economic Burden
2870 decreased, Bcl-2 leads to Cell injury/death
2873 decreased, Bcl-2 leads to Increase, Cell death
2871 increased, Bax leads to Cell injury/death
2874 increased, Bax leads to Increase, Cell death
2876 Increased fat mass leads to Recruitment of inflammatory cells
2901 Increased fat mass leads to Increased cytokine expression
2880 ERa inactivation leads to Increased adipocyte size
2881 ERa inactivation leads to Increased adipocyte numbers
2906 ERa inactivation leads to increased lipid accumulation
2929 ERa inactivation leads to Decreased, Mitochondrial fatty acid beta-oxidation
2930 ERa inactivation leads to Increased, Reactive oxygen species
2899 Increased adipocyte size leads to Increased fat mass
2898 Increased adipocyte numbers leads to Increased fat mass
2900 increased lipid accumulation leads to Increased fat mass
2877 Conjugation, GSH leads to Depletion, GSH
2902 Increased cytokine expression leads to Increase in inflammation
2885 Increase, Glucuronidation of T4 leads to Increased, Clearance of thyroxine from serum
2910 Increase, Androgen receptor leads to Alterations, Cellular proliferation / hyperplasia
2912 prostatic intraepithelial neoplasia leads to Prostate cancer
2920 Increase, Gonadotropins concentration in plasma leads to Reduction,Testosterone concentration in plasma
2921 Reduction,Testosterone concentration in plasma leads to Reduction, Plasma 17beta-estradiol concentrations
2925 Reduction,Testosterone concentration in plasma leads to Reduction, the ratio of E2/11-KT in plasma
2923 Reduction, the ratio of E2/11-KT in plasma leads to Reduction, Plasma vitellogenin concentrations
2919 Increased, gene expression of AR leads to Increase, Gonadotropins concentration in plasma
2934 Impaired insulin signaling leads to Insulin resistance
2942 Activation of MEK, ERK1/2 leads to Increase, intracellular calcium
2938 Decreased, Viable Offspring leads to Decrease, Population growth rate
2939 Increased LCN2/iron complex leads to Increased intracelluar Iron
2940 Increased intracelluar Iron leads to Neuronal dysfunction
2951 Increased intracelluar Iron leads to Oxidative Stress in Brain
2955 Disruption, neurotransmitter release leads to Impairment, Learning and memory
2970 Epigenetic modification process leads to Expression of factors ruling proliferation, modified
2971 Expression of factors ruling proliferation, modified leads to Increase, Hyperplasia (glandular epithelial cells of endometrium)
2974 SULT1E1 inhibition leads to Increased, estrogens
2978 IAV binds receptor leads to IAV cell entry
3030 IAV cell entry leads to immune mechanisms antagonized
2983 Angiogenesis disfunction leads to Increase, Vascular disrupting effects
3018 Increase, Vascular disrupting effects leads to Angiogenesis disfunction
2985 Activation, HIF1α leads to Activation Sema6A
2986 Activation Sema6A leads to Activation, Dll4-Notch pathway
2987 Activation, Dll4-Notch pathway leads to increased，Vascular endothelial dysfunction
3011 Activation, Dll4-Notch pathway leads to Increase, Vascular disrupting effects
2989 Activation of PPAR leads to Increase, Oxidative Stress
2990 Activation of PPAR leads to Activation of MMP-2 MMP-9
2991 Activation of PPAR leads to Activation of angiopoietin like protein 4
2992 Activation of PPAR leads to Activation of Angiogenic cytokines
2997 Abnormal expression of NO leads to increased，Vascular endothelial dysfunction
2994 Activation of MMP-2 MMP-9 leads to increased，Vascular endothelial dysfunction
2995 Activation of angiopoietin like protein 4 leads to increased，Vascular endothelial dysfunction
2996 Activation of Angiogenic cytokines leads to increased，Vascular endothelial dysfunction
3010 Activated ANG/Tie2 pathway leads to Increase, Vascular disrupting effects
3020 Activated ANG/Tie2 pathway leads to increased，Vascular endothelial dysfunction
3012 Activated BMP/TGF-beta pathway leads to Increase, Vascular disrupting effects
3021 Activated BMP/TGF-beta pathway leads to increased，Vascular endothelial dysfunction
3013 Activated Wnt/Frizzled pathway leads to Increase, Vascular disrupting effects
3022 Activated Wnt/Frizzled pathway leads to increased，Vascular endothelial dysfunction
3015 Activated AKT/ERK/PI3K pathway leads to Increase, Vascular disrupting effects
3024 Activated AKT/ERK/PI3K pathway leads to increased，Vascular endothelial dysfunction
3016 Inhibition VEGF/VEGFR pathway leads to Increase, Vascular disrupting effects
3025 Inhibition VEGF/VEGFR pathway leads to increased，Vascular endothelial dysfunction
3028 Vascular barrier disruption leads to Increase, Vascular disrupting effects
3029 Impaired Platelet Aggregation leads to Increase, Vascular disrupting effects
3032 Angiogenesis dysfunction leads to Increase, Vascular disrupting effects
3036 Activation, RyR leads to Increased, glutamate
3040 Opening VGCCs leads to Increased, Intracellular Calcium overload
3051 Caspase activation leads to Increase, Cell death